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CAROTID PLAQUE AND INTIMA MEDIA THICKNESS IN THE ASSESSMENT OF 
CARDIOVASCULAR RISK 
 
Trina Thompson, DrPH 
University of Pittsburgh, 2006 
 
Over the past decade significant advances have been demonstrated in the prevention and 
treatment of cardiovascular disease (CVD).  Despite these major strides, CVD continues to be 
our nation’s most significant cause of morbidity and mortality.  The risk status of asymptomatic 
persons varies greatly and thus requires a range of intense screening and interventions.  This 
dissertation focuses on subclinical CVD measures and a new methodology that will improve 
CVD assessment in research and eventually improve primary prevention efforts.   
There are three related projects, each of which uses noninvasive carotid ultrasound to 
assess cardiovascular risk.  Project one focuses on an elderly population and evaluates the 
association of calcified carotid plaques with cardiovascular outcomes.  Plaque characterization is 
a new research interest with the aim of identifying what makes one plaque more dangerous than 
another.  As plaques age, they often become more complicated and calcify.  However, the 
significance of calcification in the carotid arteries is poorly understood.  In this project, I assess if 
carotid calcification is predictive of cardiovascular outcomes. 
For project tow, a different high cardiovascular risk population, women systemic lupus 
erythematosus (SLE) is studied.  Women with SLE have significantly high risk of myocardial 
infarction compared to women without SLE.  The role that lupus-related risk factors play in 
cardiovascular disease progression above traditional risk factors is unclear.  With carotid 
ultrasound, associations between intima-media thickness and plaque with both cardiovascular 
and SLE-specific risk factors are assessed.  
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The final project documents development of new computerized assessment of carotid 
artery plaques.  Over the past decade both ultrasound and computerized assessment tools have 
improved which creates opportunity for improved plaque assessment in vivo.  This methodology 
will characterize plaques, possibly identifying which plaques are dangerous.  A novel plaque 
characterization software is paired with ultrasound scans to execute this methodology in the 
Ultrasound Research Laboratory.  Included are software considerations, protocol development, 
staff training, worksheet design, quality control procedures, and a pilot study to evaluate the 
reproducibility of the measure.  This research has public health significance by developing new 
cardiovascular risk assessment techniques which may lead to improved primary prevention and 
research methods. 
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1 INTRODUCTION 
Atherosclerotic plaques are the cause of strokes and heart attacks, but we still know little about why 
one arterial plaque causes an event and another one does not. While degree to which a plaque 
narrows a vessel and reduces blood flow was initially thought to be the cause of symptoms, newer 
research suggests that smaller plaques cause more events because of their unstable composition.  
Technologies to study plaque characterization are just emerging and carotid ultrasound is a medically 
acceptable, low cost, widely accessible method to study plaque characteristics. In the last decade, we 
have learned that certain carotid plaque characteristics are associated with increased risk of cerebral 
events.  Yet relationship between carotid plaque composition and coronary events has not been 
studied.   
1.1 FOCUS OF DISSERTATION 
This dissertation uses various noninvasive subclinical plaque measures to evaluate risk of 
cardiovascular disease in high risk populations.  In the first project, the relationship of calcified 
carotid plaques is evaluated with CVD outcomes in an elderly population.  In project two, the 
relationship of plaque presence, number and progression with cardiovascular risk factors is evaluated 
in a high risk group of women with lupus erythematosus.  And finally, in the third project, the use of a 
new plaque analysis software is planned and executed for research use.  This software is cutting-edge 
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Source: CDC/NCHS 
technology that will lead to better understanding of plaque composition and plaque vulnerability.  A 
formal reproducibility study is executed and analyzed as part of project three. 
1.2 PUBLIC HEALTH SIGNIFICANCE 
Cardiovascular disease (CVD) continues to be the leading cause of death in the Nation for both men 
and women, with >64 million people afflicted.(1;2) (Figure 1-1) CVD includes hypertension, 
myocardial infarction, chest pain (angina), congestive heart failure and cerebrovascular events (CVA 
and TIA). The risk for heart attack and death among persons with CVD is five to seven times higher 
than among the general population. The risk of CVD increases with age and also in certain diseases 
such as systemic lupus erythematosus, polycystic ovary disease and diabetes mellitus. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1-1:  U.S. Causes of Death 
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The annual cost of CVD to the nation is projected to exceed $351 billion in 2003.(3)  Yet 
these estimates do not convey the full impact of CVD from cognitive impairment after stroke and 
dementia.(4)  Trends of the global burden of CVD over the next two decades support the prediction 
that heart disease and stroke will persist as the leading causes of death and disability worldwide 
unless effective public health action is taken to prevent them.(5;6) 
Several factors accentuate this health concern. First is our aging population because CVD 
events and deaths increase with age (Figure 1-2). Over the next two decades, the number of 
Americans over 65 will increase significantly, from ~34 million in 2000 to more than 53 million in 
2020.(7)  Heart disease deaths are projected to increase sharply between 2010 and 2030, and the 
population of heart disease survivors is expected to grow at a much faster rate than the U.S. 
population as a whole. Marked increases in numbers of stroke deaths are also predicted.(8) Second, 
overweight and obesity is an increasing concern and known risk factor. Obesity affects a large 
proportion of the U.S. population—55 percent of adults—and 15% children(9). Obesity increases risk 
of illness from high blood pressure, high blood cholesterol and other lipid disorders, type 2 diabetes, 
CHD, stroke, and other diseases.  Lastly, due to the obesity epidemic, the prevalence of diabetes 
mellitus (DM) is increasing,  DM is a high risk disease for CV complications. These changes 
collectively will constitute a major increase in the nation’s CVD burden, accompanied by increasing 
demands for related health care services, increases in health care expenditures, lost income and 
productivity, and prevalence of disease, disability, and dependency. 
Cardiovascular disease is termed the silent killer because many cardiovascular events occur 
without warning.  Fifty percent of MI’s occur without any symptoms and 10% of strokes occur 
without warning.  Many of the MI’s lead to death before medical interventions occur.  The standard 
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Source: NHLBI’s ARIC surveillance study, 1987-2000. 
Framingham Risk Assessment fails to identify many at risk when they are asymptomatic.  Therefore, 
additional new techniques are needed to identify individuals at high risk for CV events.   
 
 
 
 
 
 
 
 
 
 
Figure 1-2: Annual Rate of First Heart Attacks by Age, Sex and Race 
 
 
Past research has provided the first steps into effective CVD prevention and mortality 
reduction.  Included in this research have been subclinical measures such as intima-media thickness 
using B-mode ultrasound and ankle arm index.  The results of these measures have led to treatment 
and modification of important risk factors. For example the reduction of high blood pressure and 
cholesterol, increased exercise, smoking cessation, and antiplatelet therapy has impacted 
cardiovascular disease.  Newer strategies focus on weight control, initiating preventative measures 
earlier (beginning in childhood), and increasing public education.  However, still half of all heart 
attacks occur in individuals with normal risk factor levels. 
 Healthy People 2010 has recommended using noninvasive methods to identify at-risk 
people for heart disease.(6)  This research will contribute directly to the accomplishment of that goal 
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by testing the usefulness of subclinical measures in two high-risk populations and by the 
development of a novel protocol to assess carotid plaque characteristics. 
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2 INTRODUCTION TO PROJECT 1 
In early research, degree of stenosis with resulting altered blood flow was identified as a risk factor 
for stroke.  Today we know that the components of plaques may be more important than the stenosis 
created by the plaque.  One component of plaques that is poorly understood is the presence of 
calcification.  In the first project of this dissertation, calcification of carotid plaques is used to assess 
the relationship with CV outcomes in an elderly, high CVD risk population. 
 
8 
CALCIFIED CAROID ARTERY PLAQUES PREDICT CARDIOVASCULAR OUTCOMES 
IN THE ELDERLY 
Submitted to Atherosclerosis, Thrombosis and Vascular Biology for publication 
 
1Trina Thompson MPH, 1Rachel P. Wildman, PhD, 1Anne Newman MD, MPH, 1Sarah 
Brockwell PhD, 1Kim Sutton-Tyrrell DrPH 
 
1Department of Epidemiology, Graduate School of Public Health, University of Pittsburgh, PA 
 
 
 
9 
2.1 ABSTRACT 
Background:  Plaque composition using ultrasound is getting attention to identify patients at high 
risk for cardiovascular disease. Calcification of plaques prevents complete assessment with 
ultrasound and thus are overlooked as useful predictor. We explored whether calcified carotid 
plaques are able to predict cardiovascular outcomes in older adults. 
Methods and Results: Participants included 187 hypertensive and 187 normotensive adults 
≥  60 years who underwent a duplex scan to identify the presence of calcified carotid plaques.  
Participants were followed for incident cardiovascular events and death for 11 years.   
Participants with calcified carotid plaques had higher mortality and cardiovascular event rates 
than those without plaque or without calcification of plaques (p<0.001). 
Using Cox univariate regression and controlling for age and male sex, higher systolic blood 
pressure, pulse pressure, glucose and the presence of calcified carotid plaques were associated 
with.mortality.  Calcified plaques and untreated hypertension were significantly associated with to 
time-to-any CVD event (p <0.001).  
Conclusions:  Calcified carotid plaques predict mortality and cardiovascular outcomes above 
other common risk factors in the elderly. Carotid calcification may serve as an additional 
cardiovascular risk factor in the elderly. 
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2.2 INTRODUCTION 
A key approach in combating cardiovascular disease is identifying the factors that put patients at 
highest risk and detecting them early in the course of disease.  One of the factors that is gaining 
attention is the evaluation of plaque composition.(1)  Investigators have focused on identifying 
plaque characteristics that make them vulnerable to rupture.  Studies of coronary plaques have 
identified vulnerable plaques as having a lipid core with a thin fibrous cap and often the presence of 
thrombus.(2)  Calcification is an integral part of the evolution of plaques and may also contribute to 
plaque vulnerability.(2-4) 
Because disease in the carotid arteries is a marker of disease in the coronary arteries, 
investigators have begun to use carotid ultrasound as a way to non-invasively study plaque 
characteristics.  Carotid plaque characteristics have consistently been associated with cerebrovascular 
outcomes.(5-9)  However, one major problem with these studies is that calcified plaques are often 
excluded, primarily because shadowing caused by calcification makes plaque analysis difficult. 
(6;8;10;11)  Thus, the ability to evaluate calcification as a marker of subsequent events is lost.  This 
is of particular concern when evaluating populations where vascular calcification is common, such as 
patients with diabetes (12), end-stage renal disease,(13-15) the elderly.(2;16)  The purpose of this 
study is to test whether calcified carotid plaques specifically are able to predict CV outcomes in a 
population of older adults. 
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2.3 METHODS 
Participants 
This study includes hypertensive (n=187)and normotensive (n=187) participants who underwent 
carotid duplex scans at baseline.  The hypertensive participants were recruited from the Systolic 
Hypertension in the Elderly Program (SHEP) at the Pittsburgh field center.(17;18)  SHEP was a 
muticenter randomized clinical trial designed to test the efficacy of treating isolated systolic 
hypertension in adults ≥60 years old. Screening was carried out in retirement centers, churches and 
other locations where healthy elderly adults could be identified. To be eligible, participants were ≥60 
years old, had systolic blood pressure (SBP) of 160-219 mmHg, and diastolic blood pressure of <90 
mmHg.  Exclusions included recent myocardial infarction (MI), stroke (CVA) with residual paresis, 
uncontrolled congestive heart failure (CHF), peripheral arterial disease (PAD) with evidence of tissue 
injury or loss, transient ischemic attacks (TIA) with associated carotid bruit, and contraindication to 
study medications. Detailed screening and exclusion criteria have been previously reported.(17;19)  
The hypertensive group was randomly assigned to receive either stepped care BP treatment (active 
arm) or matching placebo medication (placebo arm) using a double-masked design.  Complete 
description of medication therapy was previously reported.(20) 
A normotensive group (N=187) was recruited during the last year of SHEP from the 
Pittsburgh site.  The same SHEP screening process was used for the normotensives, except systolic 
blood pressure (BP) criteria was <160mmHg.  Nomotensive participants were stratified by age to 
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allow adequate adjustment for age between the hypertensive and normotensive groups to ensure the 
same distribution between the hypertensive and normotensive groups was maintained.  
Both groups were followed for 11 years by telephone contact.  Only 10 (5%) SHEP and 3 
(2%) normotensives were lost to follow-up. All participants signed informed consent approved by the 
institutional review board at the University of Pittsburgh.  
 
Outcome Measures 
The outcome measures were any cardiovascular event (CVD), any cerebrovascular event and death 
from any cause.  Any CVD event included cardiovascular and cerebrovascular events.  The 
cardiovascular events included CVA, TIA, MI, hospitalization for unstable angina, coronary 
revascularization, congestive heart failure, and death from cardiovascular cause. Any cerebral event 
was limited to TIA or CVA.  Deaths were verified by review of hospital records and death certificates 
and were categorized as cardiovascular or other.  
 
Scanning Protocol 
A 5 MHz linear array transducer on a Toshiba 270 (Tustin, CA ) was used to obtain B-mode images 
at the Ultrasound Research Laboratory at the University of Pittsburgh, in Pittsburgh.  The presence of 
calcified lesions in the proximal and distal common carotid artery (CCA), the carotid bifurcation, and 
the proximal internal carotid arteries (ICA) bilaterally were recorded.  Calcification was considered 
present when acoustic shadowing (blackness) was seen behind a bright plaque.  Shadowing occurs 
when the ultrasound waves cannot penetrate a dense lesion and the waves scatter leaving a void 
behind the plaque.  Two variables served as outcomes 1) a three-level categorical variable to indicate 
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absence of plaque, presence of noncalcified plaque, and presence of calcified plaque and 2) a 
binomial variable indicating the presence of  no or noncalcified plaque and calcified plaque.  
 
Statistical Methods 
Descriptive data were assessed for the total group as well as stratified by hypertension.  Continuous 
variables were reported as mean (+/- SD) and categorical variables as percent. Two-sided Student t-
tests (for normally distributed data) and Wilcoxon (not normally distributed) were used to assess 
differences in subclinical risks factors in each group. Kaplan-Meier life-table methods were used to 
estimate mortality, any event, cardiac event, and any cerebral event for those with no plaque, non-
calcified plaques, and calcified plaques, separately. In multivariate analyses, the presence of calcified 
plaques was assessed using a two level variable, because there were too few participants with no 
plaque.  Thus plaque categorizes were 1) no or noncalcified plaques and 2) calcified plaques.  
Analysis of mortality included all deaths regardless of the cause.  The log rank statistic was used to 
determine whether the survival curves differed, with p<0.05 considered statistically significant. 
Univariate Cox associations were used to select the covariates for building the final Cox regression 
model. Age and sex were controlled for in the final multivariate Cox regression model.  Statistical 
analysis was performed using SAS version 8.02 (SAS Institute Inc., Cary, NC).   
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2.4 RESULTS 
Participant Population 
Baseline characteristics at the time of entry were compared for the hypertensive and normotensive 
groups (Table 2-1). As previously reported, age and race distributions were comparable: each were 
about 40% male and 99% Caucasian.(18)  The hypertensive participants had higher mean diastolic 
blood pressure and BMI, and were less likely than normotensive participants to have ever smoked (all 
p values < 0.01). With respect to laboratory values, the hypertensive group had higher mean total 
cholesterol (p <0.001), LDL, triglycerides, and creatinine, (all p values <0.01) and lower HDL (p 
<0.03).  
 
Plaque prevalence 
The prevalence of plaque in the overall study participants was 93% (344/370). Plaque prevalence was 
96% (177/184)in the hypertensive group and 90% (167/186) in the normotensive group (p <0.016).  
Calcified plaque was more prevalent in the hypertensive group (74%) than in the normotensive group 
(55%) (p<0.001).  The mean age of those with calcified plaques was 73 years and of those with 
noncalcified plaques was 69.5 years (p<0.001). Overall mortality was 25% (n=93) over the 11 year 
follow-up period. Of those who died, 84% (n=78) had calcified plaques and 16% (n=15) had none or 
non-calcified plaques (p<0.001).  
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Mortality  
Participants were followed for vital status and CV events.  The 11-year survival rates were 91% 
among those with no plaques, 82% among those with noncalcified plaques, and 55% among those 
with calcified plaques (Figure 2-1).  Risk factors associated with mortality by Cox univariate 
regression analysis were age, male sex, higher systolic blood pressure, pulse pressure, glucose and 
the presence of calcified carotid plaques (Table 2-2:  Project 1 Univariate associations of risk factors 
to time-to-mortality and time-to-any CVD event). After controlling for age and sex, the presence of 
calcified plaques, glucose and the untreated hypertensive group remained significant for mortality (p 
<0.003 for all).  Calcified plaque was significantly associated with mortality, independent of 
hypertension.  The relative risk in the hypertensive group was 2.7 and in the normotensive group 3.7 
(p <0.008 for both) (data not shown).  
 
Time to any Cardiovascular (CVD) events 
Participants with calcified carotid plaques had a higher event rate than those without plaque or 
calcification of plaques (p<0.001) (Figure 2-2). The 11-year event-free rates were 86% among those 
with no plaques, 67% among those with noncalcified plaques, and 42% among those with calcified 
plaques (Figure 2).  As expected, traditional risk factors associated with time-to-any CVD event were 
age, male sex, higher systolic blood pressure, pulse pressure (all p values < 0.001), total cholesterol, 
LDL, triglycerides (p values 0.01), and lower HDL (p<0.001) (Table 2-2). After controlling for age 
and male sex, calcified plaques and the hypertensive control group remained significantly associated 
with to time-to-any CVD event (p <0.001) (Table 2-3).  Calcified plaque was significantly associated 
with any CVD event, independent of hypertension.  The relative risk in the hypertensive group was 
1.9 and in the normotensive group 2.8 (data not shown). 
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Time to any Cerebrovascular event  
When cerebral and coronary events were analyzed separately, only cerebrovascular event rates 
remained significantly different between the calcified vs. no plaque and noncalcified plaque groups 
(p<0.002) (Figure 2-3).  Using multivariate Cox regression, after controlling for male sex and age, 
calcified carotid plaques (RR 3.3) and the hypertensive participants on placebo (RR 3.5) were at 
highest risk of developing a cerebrovascular event (p <0.01) (data not shown). 
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2.5 DISCUSSION 
This study shows that among older adults, the presence of calcified carotid plaque predicts 
cardiovascular outcomes.  Calcified plaques were associated with death, overall CVD events, and 
cerebrovascular events specifically.  These data clearly show that even in the absence of clinically 
important stenosis, calcified lesions provide prognostic information. 
This is the first ultrasound study to show that the presence of calcified carotid plaques in an 
elderly population is related to CV outcomes other than stroke.  Among older adults in the 
Cardiovascular Health Study (CHS), hyperechoic and heterogeneous carotid plaques were related to 
transient ischemic attacks and strokes, using ultrasound, but associations with other cardiovascular 
outcomes were not evaluated.(21)  In chronic renal patients, peripheral vascular calcification was 
associated with myocardial infarction measured radiographically(12)and with ultrasound(14) yet, no 
study has looked at carotid calcification specifically.  
There are numerous reasons why calcified plaques may be related to outcome.  First, calcified 
carotid plaques are likely a marker for coronary artery calcification which has been shown to be 
predictive of overall plaque burden (22-24);(25) as well as CV outcomes.(26;27)  Second, it is 
possible that calcification may identify a subset of plaques that are vulnerable.  Naghavi described 
two types of vulnerable plaques that contain calcification 1) a calcified nodule within or very close to 
the fibrous cap that can protrude through and rupture the cap and 2) severe calcification within a 
chronically stenotic plaque with old thrombus and an eccentric lumen. (1)   It is hypothesized that 
some plaques go through repeated cycles of rupture, bleeding, and healing complicated by 
inflammatory reactions(2;28;29) which favor complicated plaque composition and calcification. (2)  
18 
Carotid ultrasound can characterize these different plaque features.(5;6;10;30-42) Studies report 
differing plaque characteristics for symptomatic and asymptomatic patients, (8;9;43)  but the exact 
plaque composition that is thought to be associated with vulnerability is inconsistent.(6;21;41;44;45) 
On ultrasound, complicated plaques present as heterogeneous which often contain calcium(5;46) and 
are associated with CV outcomes.(21;29;45;47-49)   
A third mechanism linking calcified plaques to outcome relates to plaque age and the 
developmental stages of plaque growth.  Calcification occurs in the later stages of plaque 
development after going through multiple cyclic changes. Thus calcification probably indicates 
plaques that are older.  Calcification may develop as plaques go. Among older adults, the high 
prevalence of glucose intolerance, subclinical cardiovascular disease, and reduced renal function that 
alters calcium and phosphorus metabolism may all contribute to calcified plaques.  Thus, calcium 
may indicate adverse metabolic processes that are indicative of aging and would be associated with 
events.  More research is needed to understand the role of calcified carotid plaques but this study 
shows that carotid calcification should not be dismissed because it predicts CV events in the elderly.  
We found that calcified carotid plaques were strongly associated with stroke outcomes.  This 
is consistent with findings from the Cardiovascular Health Study where both heterogeneous and 
calcified plaques were more prevalent among older adults with strokes and transient ischemic 
attacks.(50)  One reason for this may be that calcified plaques are a marker for vascular stiffness.  
People with calcified plaques may also be at risk for medial wall calcification which has been linked 
to vascular stiffness in animals (51;52) and diabetic patients.(53)  As the aorta stiffens, its critical 
cushioning effect is lost, exposing the brain and kidneys to damaging cyclic pressure.(54)  Central 
artery stiffening also leads to increases in cardiac afterload and low coronary filling.  Thus if calcified 
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carotid plaques are a marker for arterial stiffening, then this may explain the link with CV outcomes 
as well.   
In conclusion, calcified carotid plaques predict mortality and cardiovascular outcomes, above 
other common risk factors.  The presence of calcified carotid plaques may be a marker of 
complicated and vulnerable plaques in other vascular beds, especially the coronary arteries.  The 
presence of calcified carotid plaques may serve as an additional CVD risk factor in the elderly. 
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Table 2-1:  Project 1 Population Characteristics 
Risk Factor Hypertensive s 
n=187 
 
Normotensive s 
n=187 
Combined 
N=374 
p-value for 
difference between 
cases and controls 
Male sex % 40% 41% 151 (40%) 0.75 
White race % 99% 98% 370 (98.7%) 0.51 
Ever Smoke % 40% 54% 176 (47%) 0.007 
Current Smoke % 10% 12% 40 (11%) 0.50 
Calcified plaques % 74% 55% 65% <0.001 
 Mean SD Mean SD Mean  
Age 72.3 6.2 71.3 6.32 71.8 0.12* 
Systolic blood pressure 
(mmHg) 
170.4 8.7 126.8 13.1 148.6 <0.01† 
Diastolic blood pressure 
(mmHg) 
78.6 6.8 69.3 8.4 74.0 <0.001† 
Total cholesterol mg/dl 241.8 42.5 219.5 39.9 230.6 <0.001† 
High density lipoprotein 
mg/dl 
51.9 12.7 55.1 14.6 53.6 0.03* 
Low density lipoprotein 
mg/dl 
157.4 39.4 140.1 35.9 148.5 <0.01* 
Triglycerides mg/dl 166.3 96.6 123.4 72.1 144.7 <0.01† 
Glucose mg/dl 100.8 29.3 109.4 19.6 105.2 <0.01† 
Body mass index 28.0 6.1 25.6 4.5 26.8 <0.01† 
Creatinine mg/dl 1.0 0.2 0.91 0.21 0.98 <0.01† 
Lipoprotein (a) mg/dl 14.2 16.8 12.4 16.6 13.2 0.31* 
* t-test   † Wilcoxon 
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Table 2-2:  Project 1 Univariate associations of risk factors to time-to-mortality and time-to-any CVD event 
 Time to Death 
N=374 
Time to Any CVD Event 
N=374 
Variable RR 95% CI p-value RR 95% CI p-value 
Age per 5 yrs 1.56 1.33-1.82 <0.001 1.32 1.16-1.50 <0.001 
Male sex 2.64 1.74-4.00 <0.001 2.62 1.88-3.65 <0.001 
Systolic blood pressure per 10 
mmHg 
1.21 
 
1.11-1.33 <.001 1.16 1.08-1.25 <0.001 
Diastolic blood pressure per 10 
mmHg 
1.11 0.87-1.40 0.408 1.11 0.92-1.34 0.264 
Pulse Pressure per 10 mmHg  1.27 1.15-1.41 <0.001 1.20 1.11-1.30 <0.001 
Chol 25 mg/dl 1.0 0.88-1.13 0.932 1.12 1.02-1.23 0.015 
HDL per 10 mg/dl 0.59 0.39-0.88 0.01 0.57 0.41-0.79 <0.001 
LDL per 25 mg/dl 1.01 0.87-1.17 0.891 1.14 1.02-1.27 0.017 
Triglycerides per 25 mg/dl 1.01 0.96-1.10 0.656 1.05 1.01-1.09 0.017 
Glucose per 25 mg/dl 1.27 1.07-1.50 0.007 1.15 0.98-1.35 0.080 
Basal Metabolic Index per 5 unit 1.11 0.93-1.32 0.265 1.12 0.97-1.30 0.117 
Ever Smoke 0.67 0.45-1.01 0.055 0.73 0.52-1.04 0.082 
Calcified plaque y/n § 3.89 2.23-6.77 <0.001 2.65 1.78-3.95 <0.001 
Plaque 
 None 
 Uncalcified  
 Calcified  
 
1.0 
1.80 
6.30 
 
 
0.41-7.96 
1.55-25.69 
 
 
0.441 
0.010 
 
1.0 
2.67 
6.22 
 
 
0.81-8.81 
1.97-19.61 
 
 
0.106 
0.002 
 
Blood Pressure Status 
 Controls 
 Hypertensive, active arm * 
 Hypertensive, placebo arm ** 
 
1.0 
1.68 
3.11 
 
 
1.04-3.02 
1.92-5.04 
 
 
0.037 
<0.001 
 
1.0 
1.45 
2.97 
 
 
0.95-2.22 
2.03-4.35 
 
 
0.088 
<0.001 
§ yes= calcified plaques no=includes no plaque and noncalcified plaques   
* Hypertensive group taking antihypertensive medication ** Hypertensive group taking placebo  
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Table 2-3:  Project 1  Multivariate associations of CVD risk factors with time-to-mortality and time-to-any CVD 
event 
 
 Time to Death 
N=374 
Time to Any CVD Event 
N=374 
Variable RR 95% CI p-value RR 95% CI p-value 
Age per 5 years 1.43 1.21-1.70 <0.001 1.17 1.02-1.34 0.018 
Male sex 2.46 1.60-3.77 <0.001 2.64 1.88-3.69 <0.001 
Calcified plaque y/n§ 2.77 1.57-4.86 <0.001 2.14 1.42-3.22 <0.001 
Blood Pressure Status 
 Normotensives 
 Hypertensive, active 
arm* 
 Hypertensive, placebo 
arm** 
 
1.0 
1.64 
2.15 
 
 
0.95-2.83 
1.31-3.52 
 
 
0.077 
0.003 
 
1.0 
1.34 
2.20 
 
 
0.87-2.08 
1.49-3.26 
 
 
0.186 
<0.001 
Glucose per 25 mg/dl increase 1.27 1.08-1.48 0.003 —— —— —— 
§ yes= calcified plaques no=includes no plaque and noncalcified plaques   
** Hypertensive group taking antihypertensive medication ** Hypertensive group taking placebo 
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Figure 2-1:  Kaplan Meier Estimates of 11 Year Survival by Presence and Type of Carotid Plaque 
 
 
 
 
 
 
 
 
 
 
Figure 2-2:  Kaplan Meier Estimate for Any CVD Event Over 11 Years by Presence and Type of Carotid 
Plaque 
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Figure 2-3:  11 Year Kaplan Meier Estimates for Cerebral Event by Presence and Type of Carotid Plaque 
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3 INTRODUCTION TO PROJECT 2 
Systemic Lupus Erythematosus (SLE) is a chronic, autoimmune disease which causes mutisystem 
organ damage through chronic inflammation and episodes of inflammatory exacerbations.  The 
disease affects mostly women and is known to increase risk for death and morbidity due to heart 
attacks and strokes.  The reason for higher risk of heart attack and stroke is not clear.  Cross-sectional 
studies have shown that both traditional and SLE-related risk factors are related to the elevated risk, 
but no longitudinal study has evaluated the association between risk factors and subclinical measures.  
In project two, a population of women with SLE undergo baseline and follow-up ultrasound testing to 
evaluate the association between traditional and SLE related risk factors with subclinical outcome 
measures.  
In this project, two ultrasound measures are utilized. One measure is the intima media 
thickness and the other is a measure of plaque burden, the number of plaques in the carotid system.  
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3.1 ABSTRACT 
Background: Women with systemic lupus erythematosus (SLE) are at higher risk of cardiovascular 
disease and death from atherosclerosis than women without SLE.  We conducted a longitudinal study 
to determine the relationship of traditional and SLE-related risk factors with atherosclerotic 
progression in this population. 
Methods: Carotid ultrasound was performed at baseline (N=282) and after an average of 4.1 
years of follow-up (n=214) on SLE women ≥  18 years recruited from the Pittsburgh Lupus Registry.  
Clinical, serological, SLE-related factors and disease treatment were evaluated. Outcomes were 
carotid intima-media thickness (IMT) and plaque presence.  
Results: Mean age was 45 years (standard deviation (SD) 10.9), mean IMT was 0.64 mm (SD 
0.14) at baseline and 0.68 mm (SD 0.15) at follow-up. Mean IMT progression was 0.01 mm (SD 
0.07) per year.  In multivariate regression analysis, age and modified SLICC (lupus disease damage 
index) were associated with baseline IMT. Serum creatinine and age were strongly associated with 
IMT progression (p <0.01) and modified SLICC and immunosuppressant non-use were borderline 
significant (p 0.04 and 0.08, respectively). Plaque prevalence was 33% at baseline and 40% at follow-
up. Plaque progression occurred in 27% of the women. In multivariate regression, age, ever smoking, 
higher systolic blood pressure, longer steroid use and antidepressant use were associated with plaque 
presence at baseline (p ≤ 0.04 for all). The primary factors associated with plaque progression were 
older age and higher triglycerides (p <0.01). Higher serum complement C3 values and duration of 
SLE disease were borderline significant (p 0.05 and 0.07, respectively).  
33 
Conclusion: Both SLE-specific and traditional risk factors are associated with progression of 
carotid IMT and plaque. These subclinical measures may be useful managing women with SLE and 
as surrogate endpoints in SLE intervention trials. 
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3.2 INTRODUCTION 
Systemic lupus erythematosus (SLE) is an autoimmune inflammatory disease that primarily affects 
women. It manifests with frequent exacerbations of inflammatory flares that may ultimately cause 
organ failure. Treatment consists of anti-inflammatory agents and immunosuppressive therapies. 
Patients with SLE are at higher risk of cardiovascular disease (CVD) compared to women of similar 
ages (1-5). Women with SLE under the age of 45 were found to have a 50 fold higher risk of 
myocardial infarction (MI) compared to women of similar age in the Framingham Offspring study(6). 
Cross-sectional and retrospective studies have shown that traditional risk factors including 
hypertension, obesity, diabetes mellitus, smoking, hyperlipidemia, hyperhomocysteinemia and 
sedentary lifestyle play a role in this accelerated atherosclerosis.(3;7;8) However, the diagnosis of 
SLE remains a strong risk factor for CVD, even after controlling for traditional risk factors. The most 
important SLE factors contributing to premature CVD remain unknown. 
Noninvasive imaging techniques have been used to explore why SLE predisposes women to 
excess CVD burden. Using these modalities, increased rates of carotid focal plaque (37.1% vs. 
15.2%)(7) and coronary calcium (30.7% vs. 8.7%)(9) have been reported in women with SLE 
compared to controls. Other studies have also found higher than expected rates of subclinical 
atherosclerosis in women with SLE.(4;5;10;11) To date, intima media thickness (IMT) and plaque 
assessment have not been used in longitudinal studies of women with SLE to evaluate rates of change 
and the factors that predict change in subclinical atherosclerosis.  The ability to measure change in 
subclinical atherosclerosis among these women would provide the option of using surrogate 
cardiovascular endpoints in clinical trials of SLE therapies.  The purpose of this study is to evaluate 
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progression of carotid atherosclerosis in SLE women and determine the relative contribution of both 
traditional and SLE-related risk factors.  
3.3 METHODS 
Patient Population 
Women were recruited from the Pittsburgh Lupus Registry Cardiovascular Study as part of a 
longitudinal NIH funded study of CVD in SLE. The registry includes patients who have been seen 
either at the University of Pittsburgh Medical Center inpatient and outpatient facilities or by 
practicing rheumatologists in the Pittsburgh Metropolitan area. Thus, the sample represents a 
community based spectrum of mild to severe SLE with minimal tertiary care center referral bias. 
These women fulfilled the 1982 American College of Rheumatology revised criteria for the 
classification of definite or probable SLE (12). The updated criteria for SLE(13) had not yet been 
published when the study began. All women 18 years of age or older were invited to participate 
regardless of a previous history of a cardiovascular event. Baseline carotid duplex scans were 
obtained in 282 women with SLE of which 214 had follow-up scans. Of the 282, ten women declined 
the follow-up exam, 43 were lost to follow-up, one woman had a carotid endarterectomy between 
baseline and follow-up, and 15 had technically inadequate scans.  Each participant provided written 
informed consent and authorization for release of medical information. The study was approved by 
The University of Pittsburgh’s Institutional Review Board.  At baseline, each participant completed 
an interview, a physical examination, laboratory tests and a carotid duplex scan. The follow-up scans 
were repeated an average of 4.2 years (range 1.8-9.7 yrs) later.  
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Measurement of Covariates/Traditional CVD Risk Factors: 
At the baseline clinic examination, age, race, education, smoking habits, family history of 
cardiovascular disease, diagnosis of diabetes, and post-menopausal status were documented. Post 
menopause status was determined by a history of total hysterectomy or amenorrhea for ≥ 1 year in 
women in the peri-menopausal age group. If post-menopausal status was uncertain, follicle-
stimulating hormone levels were measured.  
This visit also included anthropometric measurements (height, weight, and waist and hip 
circumference), two consecutive seated blood pressures (averaged) and a 12 hour fasting blood draw. 
Blood samples were used to measure total cholesterol, low-density lipoprotein (LDL) cholesterol, 
high-density lipoprotein (HDL) cholesterol and triglycerides. Lipid assays were performed at the 
Heinz Lipid Laboratory in the University of Pittsburgh Graduate School of Public Health, which is 
certified by the Centers for Disease Control and Prevention. The Friedewald equation was used to 
estimate LDL cholesterol.(14) Plasma glucose levels were determined by enzymatic assay, and 
plasma insulin levels were measured by radioimmunoassay. Hypertension was defined as an average 
systolic blood pressure of ≥ 140 mmHg , an average diastolic blood pressure of ≥ 90 mmHg, or the 
use of antihypertensive agents. Metabolic syndrome (MBS) was defined using the National 
Cholesterol Education Program (NCEP) Adult Treatment Panel (ATP) III clinical guidelines(15) as 
the presence of three or more of the following components:  waist circumference >88 cm, 
triglycerides ≥  150 mg/dl, HDL <50 mg/dl, BP ≥  130/85 mmHg, fasting glucose ≥  11 mg/dl. 
 
SLE-related disease risk factors: 
SLE disease activity and cumulative organ damage were measured by the same physician using the 
Systemic Lupus Disease Activity Measure (SLAM)(16) and the Systemic Lupus International 
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Collaborating Clinics/American College of Rheumatology (SLICC) damage index (17). The SLICC 
index measures irreversible damage from lupus or its treatment in approximately nine organ systems.  
Because the disease endpoint for this study is carotid atherosclerosis, the SLICC damage score was 
modified (SLICC mod) to remove values for cardiovascular and peripheral vascular disease to avoid 
higher scores for women with known cardiovascular damage. The modified version results are 
reported.  
Women also provided information on corticosteroid usage (past/current, maximum dose, and 
duration), and current use of hydroxychloroquine, immunosuppressants, and antidepressants. 
Immunosuppressant medications included cyclophosphamide, azathiaprine, cyclosporine and 
methotrexate. Renal disease was defined using the SLICC renal variables, which requires the 
presence of nephrotic-range proteinuria (≥ 3.5 grams/24 hrs) or renal insufficiency (glomerular 
filtration rate <50%) for at least 6 months. Laboratory studies included tests for lupus anticoagulant 
(partial thromboplastin time or dilute Russell Viper Venom time with mix), serum complement 3 
(C3), complement 4 (C4), anticardiolipin antibodies (IgG >15 standard IgG phospholipids units, IgM 
>10 standard IgM phospholipids units (Incstar, Stillwater, MN), and native DNA (dsDNA) antibodies 
(by Crithidia luciliae). Complement (C3, C4) activation is considered a critical and final common 
pathway of the immune and inflammatory processes leading to tissue destruction in SLE.  
 
Inflammatory markers:  
Serum albumin, C-reactive protein, and fibrinogen levels were measured at baseline. Fibrinogen was 
measured using a modified clot-rate assay, while an enzyme-linked immunosorbent assay was used 
for determination of C-reactive protein (CRP), and a dye binding assay for albumin.(18) These assays 
were done at the University of Vermont. 
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Carotid atherosclerosis measurements:  
Carotid ultrasound was performed at the University of Pittsburgh Ultrasound Research Laboratory 
(URL) and has been previously described.(1;19)  High resolution ultrasound machines from Toshiba 
(Model 140, Tustin, CA) equipped with a 5mHz linear array transducer were used. Vascular 
technologists were certified annually by performing overscans and overreads on ten participants per 
year. IMT intraclass correlation between sonographers was ≥ 0.90.  
Sonographers imaged the near and far walls of the common carotid artery (CCA), the far 
walls of the carotid bifurcation and the proximal internal carotid (ICA) artery bilaterally. For each 
segment, the sonographer imaged multiple planes, selected the area of thickest IMT including any 
plaque, and digitized the image.  IMT readings were performed for both baseline and follow-up 
exams, one month apart with a consistent reader using an automated edge-detection software (AMS, 
Sweden).(20)  The IMT measurements were averaged across 1 cm of each vessel segment bilaterally. 
Values from the 8 measures were then averaged to obtain the mean average IMT. Reproducibility 
within readers was assessed across 12 participants.  The intraclass correlation was 0.87.  IMT change 
was assessed on a continuous scale.  
Plaque was defined as a focal projection within the intima-media layer that was at least 50% 
greater than adjacent areas. The CCA, bulb and proximal ICA were used to report the number and 
grades of plaque, an estimate of severity. The number of plaques was totaled bilaterally and grades 
were also summed to create the plaque index (PI), an estimate of overall plaque burden. Previously 
reported intraclass correlation for plaque measures was 0.93.(21) 
Plaque progression was defined as any increase in number or size of plaques. When 
progression was based on increased plaque size, scans were reviewed and progression was verified.  
39 
Change in number of plaques ranged from -1 to 4.  The 11 women with negative change values were 
considered non-progressors.  
 
Statistical analysis:  
Descriptive statistics were reported as means [with standard deviations (SD)] and medians (with 
range) for continuous variables and as percentages for categorical variables. Univariate linear and 
logistic regression analyses were used to determine the association between baseline risk factors with 
IMT and plaque and change in these measures. Univariate associations were used to select the 
covariates for stepwise regression. The significantly associated variables (p ≤  0.05) were then used 
to build the final regression models. The multivariate progression models were adjusted for the 
baseline value (IMT or plaque) and time between scans. Progression outcomes were reported as both 
overall and annual changes. When multiple candidate variables were available to measure related 
characteristics (e.g. SBP and pulse pressure), the factor most significant (lowest p-value) in univariate 
analysis was selected for inclusion in the stepwise selection procedure. If distributional assumptions 
of the regression procedures were not met, variable transformations were considered. Statistical 
analysis was performed using SAS version 8.02 (SAS Institute Inc., Cary, NC). Standardized beta 
coefficients were reported.  
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3.4 RESULTS 
Population Characteristics at Baseline:  
The 282 women studied were predominantly White (89%), 10% were African American and 1% 
Asian or Eastern Indian (Table 3-1). This is a reflection of the racial composition of the Pittsburgh 
Metropolitan Area. They had a mean age of 45 years (SD 10.4). The average time between scans was 
4.2 years (range 1.8-9.7) and average SLE duration was 10.5 years (range 0.5-41 years). Ninety-three 
(33%) were hypertensive (92% of these treated), 41 (14.5%) had a history of CVD, and 124 (44%) 
were postmenopausal at baseline.  Among postmenopausal women, 59 (48%) were on hormone 
replacement therapy (HRT).  Thirty-six percent of women had elevated total cholesterol levels (≥ 200 
mg/dl ) and 57% had elevated LDL levels (≥ 100 mg/dl). Of those with elevated cholesterol or LDL, 
less than 5% were being treated with cholesterol lowering medication. The modified SLICC damage 
score ranged from 0-8 (median 1) and the SLAM score ranged from 0-21 (median 6).  The higher the 
SLAM and SLICC scores the more disease activity and organ damage, respectively.  These values 
demonstrate a broad range of disease activity and damage in this relatively young cohort of women 
with SLE.   
 
Prevalence and Progression of IMT and Plaque 
Among women with baseline scans (n=282) the mean IMT was 0.64 mm (SD 0.14). Of those with 
two scans (n=214), the baseline mean IMT was 0.63 (SD 0.14) and follow-up was 0.68 mm (Table 
3-1). The average total IMT change was 0.05 mm with an average annual IMT progression rate of 
0.01 mm/year (SD 0.074mm, p <0.01).  
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Prevalence of any plaque was 33% at baseline and 40% at follow-up. The majority of women 
showed no change in number of plaques (68%).  An increase in number of plaques was seen in 27% 
while 5% of women (n=11) had a decrease of one plaque.  
 
Risk Factors associated with IMT and IMT Progression 
Numerous traditional as well as SLE-related risk factors were associated with higher baseline IMT 
(Table 3-2). The strongest (p<0.001) were older age, hypertension, higher blood pressure, larger 
waist circumference, longer years of steroid use, and higher modified SLICC damage index. In 
multivariate analysis (Table 3-3), the majority of variation in baseline IMT was explained by older 
age and higher modified SLICC index. No other risk factors added further predictive value to the 
model after these two variables were included. 
A number of traditional and SLE-related risk factors were also associated with change in IMT 
including older age, years of steroid use, immunosuppressant non-use, and lower serum albumin 
(Table 3-2).  In multivariate analysis (Table 3-3), independent predictors of greater IMT progression 
were older age, lower diastolic blood pressure, higher serum creatinine, and higher modified SLICC.  
Immunosuppressant non-use was borderline significant (p 0.08).  Because kidney function is 
incorporated in the modified SLICC the model was re-run without creatinine.  When this was done, 
the association between SLICC and IMT progression was highly significant (standardized beta 0.20, 
p 0.005).   
 
Risk Factors for Plaque and Plaque Progression 
Traditional and SLE-specific risk factors were also related to plaque at baseline (Table 3-2).  The 
strongest (p<0.001) traditional risk factor associations were older age, postmenopausal status, higher 
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systolic blood pressure and higher pulse pressure. The strongest SLE-related risk factors associated 
with plaque were longer duration of SLE, longer years of steroid use, antidepressant use, and higher 
modified SLICC index.  In multivariate analysis, factors independently associated with plaque 
presence at baseline were older age, ever smoking, higher systolic blood pressure, longer steroid use, 
and antidepressant use (Table 3-3).  Many traditional and SLE-related factors were associated with 
progression of carotid plaque in univariate analyses (Table 3-2).  Primary factors independently 
associated with plaque change in the multivariate analysis were older age and higher triglycerides 
(Table 3-3).  Higher serum C3 values and duration of SLE disease were borderline significant (p 0.05 
and p 0.07, respectively) (Table 3-3).  
3.5 DISCUSSION  
The average rate of IMT progression observed among women with SLE was 0.01 mm (SD 0.03) per 
year.  SLE specific risk factors were related to both IMT and IMT change.  This rate of IMT 
progression (0.01 mm per year) appears to be high in comparison to normal populations.  Among 
age-similar women in the Women’s Healthy Lifestyle Project (WHLP), rates of IMT progression 
were less ( 0.007 mm/yr).(22)  SLE women in this group have rates closer to those seen among older 
women in the Atherosclerosis Risk in Communities (ARIC) study (aged 45-65).  IMT progression 
rates were 0.0086 mm per year (23) for women in ARIC.  Thus, the higher CVD event rates seen in 
women with SLE appear to be preceded by higher rates of subclinical disease progression.  Because 
IMT is known to be predictive of subsequent CVD outcomes (8;24;25) these data suggest that 
measures such as IMT progression might be used as surrogate endpoints in clinical trials of SLE 
therapy.  
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Both higher serum creatinine and higher modified SLICC damage index were independent 
predictors of IMT progression. The association of SLICC with IMT progression decreased when 
creatinine was also in the model because the SLICC score includes kidney function.  These findings 
suggest several things.  First, the vasculature is a target of the generalized organ damage that occurs 
with SLE.  Second, the renal damage caused by SLE either contributes to or is a marker of 
cardiovascular disease progression.  The health of the kidneys and the vasculature are intimately 
entwined and the kidneys are particularly susceptible to the consequences of vascular aging.(26) 
Thus, monitoring kidney function likely provides useful information on the vascular effects of SLE.  
This idea is supported by cross-sectional data that have shown that impaired renal function is related 
to coronary artery calcification (11)  and carotid atherosclerosis(27) among SLE women. 
In univariate analysis, immunosuppressant use was associated with slower IMT progression. 
After controlling for age, this association became borderline, probably due to inadequate power. Only 
37 women (13%) were on immunosuppressants at baseline.  This is likely a reflection of the mix of 
university and community patients with SLE enrolled in the study resulting in many patients with 
mild disease.  The association between immunosuppressants and vascular disease is consistent with 
cross-sectional data which found that cyclophosphamide non-use was associated with plaque among 
SLE women(7).  These data together suggest that more aggressive treatment for SLE may slow 
vascular aging and premature CVD.  
The 33% prevalence of carotid plaque found here is similar to other populations of SLE 
women (17%-40%).(1;5;7;8;27;28) These rates are higher than similar populations of non- SLE 
women where rates have been reported to be 11-25%.(7;8;29) The 33% prevalence found here is 
even higher than the 19.3% prevalence reported in an older population of women in The Aging 
Vascular Study (EVA, age 59-71 years).(30) Twenty-seven percent of our SLE women had plaque 
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progression, also higher than the 18.3% progression rate reported in EVA.(30) Thus, it appears that 
women with SLE develop lesions earlier and these lesions may progress faster than among normal 
women.  
Both prevalence and progression of plaque were associated with SLE-related factors after 
controlling for age. It is likely that the heightened inflammatory process in SLE contributes to higher 
CVD. Elevated serum complement (C3) was found to be related to plaque progression, (p 0.05), 
while only of borderline significance.  We have previously reported that high serum C3 levels are 
related to increased aortic stiffness in SLE women (28;31). Serum C3 has also been found to be 
associated with coronary calcification.(11).  These observations are particularly surprising because 
decreased levels of C3 (precursor of complement activation) are traditionally associated with lupus 
pathogenesis. There are two possible explanations for our observation that increased serum levels of 
C3 are associated with carotid plaque progression and vascular stiffness in lupus.  First, it may reflect 
an acute phase response.  We believe this is unlikely because other acute phase proteins such as CRP 
and fibrinogen were not associated with plaque or vascular stiffness in the same patients.  Second, 
activation of the complement system may actually contribute to plaque formation and increased 
vascular stiffness.  It is recognized that inflammation is involved in all stages of atherosclerosis 
development and complement is the final common pathway in all physiologic and pathophysiologic 
inflammatory processes.(32-35)  One direct mechanism includes increased endothelium permeability, 
leading to plasma protein influx into the arterial wall.(36) Indirectly, serum C3 may be involved 
through stiffening of the vasculature that later creates an environment where plaques are more likely 
to form. SLE-related inflammatory abnormalities may also function synergistically with traditional 
risk factors, making them particularly harmful. 
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Longer steroid use also increased risk of plaque and this is consistent with other studies.(1;4) 
Similar research has found longer steroid use to also be associated with higher IMT compared to 
controls(8) and with CAD(37).  Conversely, Roman found less use of steroids to be associated with 
plaques(7) and Asanuma found no relation between steroid use and CAC.(9)  Although the anti-
inflammatory effects of steroids may be beneficial, these agents have atherogenic potential due to the 
effects on total cholesterol, lipoproteins, blood pressure, adiposity, or through modification of the 
pathogenesis of atherosclerosis.(38-40)  Longer use of steroids did not influence plaque progression.  
Psychosocial stressors may also influence CVD progression in SLE women. Our finding that 
anti-depressant use was associated with plaque is intriguing, but difficult to interpret, since 
antidepressants may be used for reasons other than treating depression, including pain management in 
patient with SLE.  Data on depression was not collected at baseline.  However, non-SLE studies have 
repeatedly shown evidence that depression significantly contributes to the pathogenesis and 
expression of coronary artery disease (CAD) (41-44) as well as carotid plaques (45) and coronary 
calcification. (46)  Further investigation into the effects of depression on CVD in SLE is warranted.  
It should be considered that our population represents mostly Caucasians with milder cases of 
SLE than seen in a rheumatology practice.  Confirmation of SLE diagnosis was made by medical 
record review and the number of women on immunosuppressant therapy was low.  It is probable that 
progression rates of carotid plaque and IMT may be higher in other SLE cohorts. 
In conclusion, both carotid IMT and plaque progression can be measured using B-mode 
ultrasound in women with SLE.  IMT and plaque progression appear to be greater than non-SLE 
historical controls. Rates of progression are related to both SLE-related and traditional risk factors 
and these two may work in concert to increase CVD risk.  The clinical significance of this study 
impacts CVD prevention among SLE women. It appears that more aggressive treatment of SLE 
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results in slower progression of CVD.  Additionally, monitoring kidney function likely provides 
useful information on the vascular effects of SLE, detected by changes in carotid IMT.  This study 
provides data to support the use of carotid B-mode ultrasound as a surrogate endpoint in future 
clinical trials examining the efficacy of new biologic and immunomodulatory therapies for SLE. 
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Table 3-1:  Project 2 Population Characteristics at Baseline 
N=282 
Baseline Risk Factors n Percent    
White race % 248 88%    
Level of education      
≤ 12 102 33%    
13-16 125 44%    
>16 55 20%    
Postmenopausal, % 124 44%    
Hormone Replacement Therapy 
(n=postmenopausal women) 
59 48%    
Ever Smoke, % 124 44%    
Steroid use ever, % 264 94%    
Current steroid use, % 159 44%    
Current Immunosuppressant meds % * 37 13%    
Current Antidepressant use 63 22%    
Hypertension, % * 93 33%    
Metabolic Syndrome, % * 64 23%    
 n Mean (SD) Median Range 
Age, years 282 45.0 (10.9) 44.8 20-75 
SLE duration, years 279 10.53 (7.3) 9.3 0.5-41.4 
Steroid use in years 256 6.07 (6.8) 3.75 0-36 
Systolic Blood Pressure, mmHg 282 120.0 (18.2) 120.0 85-224 
Diastolic Blood Pressure, mmHg 282 78.17 (10.5) 78.5 48-110 
Pulse Pressure, mmHg 282 42.03 (13.0) 40.0 15-120 
Cholesterol, mg/dl † 282 193.88 (40.8) 186.5 106-384 
HDL, mg/dl † 282 56.56 (16.2) 54.9 21.3-119 
LDL, mg/dl † 282 111.39 (33.6) 105.0 39-227 
Triglyceride, mg/dl † 282 127.42 (83.9) 105.0 33-802 
BMI, kg/m2 † 280 27.73 (7.1) 26.34 17.03-68.97 
Serum Creatinine, mg/dl † 282 1.03 (1.3) 0.80 0.4-13.7 
Fibrinogen, mg/dl † 268 300.82 (72.6) 294.5 136-702 
C-reactive protein, mg/ml 271 4.42 (8.2) 2.10 0.2-89.8 
Complement C3, mg/dl † 281 94.81 (24.4) 94.0 30-177 
Complement C4, mg/dl † 281 21.68 (7.9) 21.0 6-47 
Albumin, mg/dl † 282 4.68 (0.4) 4.7 2.9-5.7 
WBC, 1000/mm3 † 281 5.87 (2.3) 5.4 1.8-15.0 
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Table 3-1 con’t 
 
Baseline Risk Factors n Mean (SD) Median Range 
SLAM score 280 6.86 (3.7) 6.0 0.0-21.0 
SLICC damage score, modified 281 1.28 (1.6) 1.0 0.0-8.0 
Baseline mean IMT (mm) 277 0.643 (0.1) 0.603 0.44-1.48 
Follow-up mean IMT (mm)  214 0.683 (0.2) 0.650 0.48-1.51 
IMT yearly change (mm) 214 0.011 (0.023) 0.009 -0.17 -0.11 
Time between scans (years) 214 4.19 (2.0) 3.99 1.81-9.70 
*Immunosuppressant meds included cyclophosphamide, azathiaprine, cyclosporine and methotrexate.  
Metabolic syndrome as defined by Adult Treatment Panel (ATP) III clinical guidelines:  Three or more: waist 
circ. >88 cm, triglycerides ≥  150 mg/dl, HDL <50 mg/dl, BP ≥  130/85 mmHg, fasting glucose ≥  11 mg/dl. 
Modified SLICC: excludes cardiovascular and peripheral vascular components.  Hypertension was defined as 
average systolic blood pressure of ≥ 140 mmHg , an average diastolic blood pressure of ≥ 90 mmHg or the use 
of antihypertensive agents. 
† To convert values to SI units, multiply: cholesterol, HDL, LDL by 0.0259 for mmol/L, triglycerides by 0.0113 
mmol/L, creatinine by  88.4 μ mol/L, fibrinogen by 0.0294 μ mol/L, complement C3 and C4 by 0.01 g/L, 
albumin by 10 g/L, and WBC by 1.0 x109/L.
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Table 3-2:  Project 2 Univariate Relationship of Traditional CVD Risk Factors with IMT and Plaque 
Baseline N=282, Change N=214 
 Baseline IMT IMT Change Plaque Presence y/n Plaque Change y/n 
Traditional CVD risk 
factors at baseline 
Standardized 
Beta coefficient 
p-value Standardized 
Beta 
coefficient 
p-value Odds 
Ratio 
95% CI P-value Odds 
Ratio 
95% CI P-value 
Age 0.60 <0.01 0.14 0.04 1.12 1.09-1.16 <0.01 1.09 1.05-1.13 <0.01 
SES, Level of education -0.14 0.02 -0.05 0.49 0.92 0.81-1.03 0.14 0.77 0.66-.090 <0.01 
Postmenopausal 0.45 <0.01 0.12 0.07 4.59 2.69-7.84 <0.01 3.66 1.94-6.90 <0.01 
Current Smoke -0.08 0.20 0.05 0.43 1.35 0.67-2.71 0.40 1.81 0.77-4.26 0.17 
Ever Smoke 0.17 0.01 0.10 0.16 2.28 1.37-3.72 <0.01 1.44 0.78-2.64 0.24 
Metabolic Syndrome 0.12 0.04 0.12 0.07 1.78 0.65-2.13 0.58 1.59 0.79-3.20 0.19 
Diabetes -0.02 0.77 <-0.01 0.96 0.68 0.14-3.44 0.64 4.78 1.10-20.69 0.03 
Hypertension 0.24 <0.01 <-0.01 0.94 2.07 1.25-3.46 <0.01 2.16 1.67-4.01 0.01 
Systolic Blood Pressure 0.31 <0.01 -0.08 0.23 2.59 1.79-3.74 <0.01 2.15 1.40-3.31 <0.01 
Diastolic Blood Pressure 0.12 0.05 -0.13 0.06 1.03 1.01-1.06 0.01 1.04 1.01-1.07 0.01 
Pulse Pressure 0.34 <0.01 -0.02 0.76 1.06 1.04-1.09 <0.01 1.04 1.02-1.07 0.002 
Cholesterol 0.21 0.01 -0.02 0.75 1.01 1.00-1.02 0.01 1.01 1.00-1.02 <0.01 
HDL 0.07 0.26 -0.02 0.73 1.01 0.99-1.02 0.27 1.00 0.98-1.02 0.64 
LDL 0.14 0.01 -0.02 0.78 1.01 1.00-1.02 0.06 1.01 1.00-1.02 0.01 
Triglyceride 0.15 0.01 -0.01 0.92 1.00 1.00-1.01 0.07 1.01 1.00-1.01 0.01 
Insulin 0.12 0.04 0.08 0.23 1.02 0.99-1.05 0.15 1.02 0.99-1.06 0.16 
BMI 0.19 <0.01 0.12 0.09 1.05 1.02-1.09 0.01 1.04 1.00-1.09 0.05 
Waist 0.21 <0.01 0.10 0.14 1.02 1.01-1.04 0.01 1.02 1.00-1.04 0.01 
50 
Table 3-2 con’t 
SLE - Related 
Standardized 
Beta 
coefficient 
p-value 
Standardized 
Beta 
coefficient 
p-value 
Odds 
Ratio 
95% CI P-value 
Odds 
Ratio 
95% CI P-value 
SLE duration, years 0.20 <0.01 0.11 0.11 1.05 1.01-1.08 0.01 1.05 1.01-1.10 0.01 
Steroid use ever -0.02 0.74 0.07 0.33 2.54 0.72-9.02 0.14 1.26 0.34-4.77 0.72 
Current steroid use 0.03 0.62 -0.01 0.84 1.18 0.72-1.95 0.51 1.07 0.58-1.96 0.83 
Steroid use in years 0.29 <0.01 0.15 0.04 1.08 1.04-1.12 <0.01 1.02 0.99-1.07 0.35 
Immunosuppressant 
meds 
-0.09 0.15 -0.15 0.03 0.66 0.29-1.46 0.29 1.78 0.79-4.05 0.16 
Antidepressant use 0.14 0.02 0.02 0.80 2.39 1.34-4.26 <0.01 0.83 0.38-1.83 0.65 
Serum Creatinine 0.12 0.04 0.12 0.07 1.73 0.80-3.75 0.16 2.39 0.52-11.11 0.26 
C-reactive protein 0.09 0.14 -0.04 0.60 1.01 0.98-1.04 0.46 1.01 0.98-1.04 0.55 
Complement C3 0.18 <0.01 0.03 0.69 1.01 1.00-1.02 0.38 1.02 1.01-1.03 <0.01 
Complement C4 0.17 <0.01 0.07 0.29 1.02 1.00-1.05 0.23 1.04 1.00-1.08 0.03 
Albumin -0.09 0.12 -0.14 0.04 0.76 0.40-1.42 0.38 0.99 0.46-2.13 0.98 
SLAM score -0.03 0.65 -0.05 0.51 0.93 0.86-1.00 0.04 1.06 0.98-1.15 0.15 
SLICC (modified) 0.21 <0.01 0.11 0.09 1.20 1.03-1.40 0.01 1.23 1.01-1.48 0.03 
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Table 3-3:  Project 2 Age-Adjusted Relationships of CVD Risk Factors to IMT and Plaque 
 I M T  P L A Q U E  
Risk Factors  Baseline (N=282) Change * 
(n=214) 
Presence at Baseline Progression y/n* 
 STB † p-value STB p-value OR‡ (CI) p-value OR p-value 
Age per 5 yrs 0.587 <0.001 0.318 <0.001 1.61 (1.35-1.21) <0.001 1.30 (1.06-1.58) 0.012 
Ever smoke —— —— —— —— 1.94 (1.06-3.55) <0.001 —— —— 
Systolic blood pressure per 
10 mmHg —— —— —— —— 1.24 (1.03-1.50) 0.02 —— —— 
Diastolic blood pressure 
per 10 mmHg —— —— -0.172 0.01 —— —— —— —— 
Serum Creatinine mg/dl —— —— 0.189 0.005 —— —— —— —— 
Steroid use per 5 years —— —— —— —— 1.34 (1.06-1.68) 0.01 —— —— 
Current Antidepressant use —— —— —— —— 2.05 (1.03-4.08) 0.04 —— —— 
Complement C3 per 25 units       1.43 (1.00-2.05) 0.05 
Current 
Immunosuppressant use —— —— -0.124 0.08 —— ——   
SLE duration per 5 years       1.23 (1.00-1.57) 0.07 
Triglycerides per 25 mg/dl —— —— —— —— —— —— 1.67 (1.03-1.32) 0.014 
Modified SLICC per 1 unit 0.131 0.007 0.145 <0.05 —— —— —— —— 
*adjusted for baseline value and time between scans  †STB=standardized beta coefficient  ‡OR=Odds Ratio
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4 INTRODUCTION TO PROJECT 3 
Plaque rupture is the primary cause of coronary events.  Thus, plaque characterization is a new 
way to identify characteristics of vulnerable plaques.  With the recent advances in ultrasound 
technology and customized software, plaque components are able to be identified and have been 
correlated with histology.  Subjective scales and noncustomized software have been used in the 
first attempts to study plaque characteristics.  These methods have suggested that plaque 
characteristics are more important than percent stenosis in predicting events, yet more studies are 
needed.  The computer assessment methodology to characterize plaques needs further 
development and will likely be beneficial for analyzing carotid artery plaques noninvasively in 
the future.  A first step to using computer assessment methods is to develop and standardize 
protocols for use in population-based research.  At the Ultrasound Research laboratory at the 
University of Pittsburgh, carotid ultrasound is used to study atherosclerosis. Plaque 
characterization is not yet included in the carotid ultrasound protocol and would add a new 
dimension to our research efforts.  This section describes the components of implementing 
plaque assessment in the lab.  It includes the following:  1) development and use of scanning, 
and reading protocols 2) training of staff in use of scanning and reading protocols 3)  
development and refinement of reading software, and 4) design and analysis of reproducibility 
study for the new measures.  
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4.1 MECHANISMS OF VULNERABLE PLAQUES 
Plaque composition and vulnerability have emerged as being the primary factor underlying 
cardiovascular events.(1;2)  To date, soft and lipid-rich plaques have been reported to be more 
likely than fibrous or collagen-rich plaques and calcium to rupture or cause symptoms. (3-5) 
More research focusing on plaque morphology is needed to identify the types of plaques that 
cause events.  However, tools to evaluate plaque characteristics obtained by noninvasive 
methods are just recently available. 
 What makes one lesion vulnerable compared to another is not completely understood and 
it is an ongoing focus of research.  Acute coronary syndromes are caused by three main 
mechanisms that cause dangerous thrombi.  Of these, plaque rupture (65-70%) is the most 
common, (6;7) plaque erosion (25-30%) is second and calcified nodules that protrude into the 
lumen (2-5%) are seen less often.(4)  Plaques typically have a fibrous cap that covers the lesion 
and this often becomes thin, making it vulnerable to rupture. (1;4)  Rupture activates two 
processes when the lipid core becomes exposed.  First, a mechanical process occurs in which 
platelets quickly adhere to the injured vascular surface and fibrin and platelets rapidly 
accumulate to form a thrombus. The thrombus occludes the vessel lumen and restricts flow 
distally causing an acute coronary syndrome.  The second process is an inflammatory process 
beyond the focus of this dissertation.  
To prevent events, a tool which will allow identification of high risk plaques before 
symptoms occur is needed. Ultrasound and computer software used together have the potential to 
meet this goal.  Because disease in the carotid arteries is a marker of coronary artery disease, 
investigators have begun to use carotid ultrasound as a way to noninvasively study plaque 
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characteristics.  Carotid plaque characteristics have been studied preoperatively with ultrasound 
and compared postoperatively with histological assessment with good agreement. The scales 
have been primarily subjective and difficult to reproduce or track changes over time.  Plaques 
that appear echolucent (black) are correlated with hemorrhage and lipid cores (8-11) and are 
often present with cerebrovascular symptoms.  Other studies are similar, reporting that thrombus, 
fresh blood, and lipids are present in vulnerable carotid lesions.(6;7;12-17) Most of these studies 
have used subjective ultrasound classifications to characterize plaques.  The reproducibility of 
subjective scales are fair and therefore, a few studies have begun using nonspecialized imaging 
software to assess plaque characteristics. One problem with these tools is that they are not able to 
discern normal ultrasound signals from ultrasound artifacts and signal noise.    Computerized 
plaque analysis is a new tool that will improve plaque characterization in vivo and improve 
standardization of plaque assessment for research.Thus, this dissertation takes steps to improve 
and provide specialized quantitative software to evaluate carotid plaque characteristics for CVD 
research. Automated software will provide a way to monitor plaques for clinical trials of 
atherosclerotic interventions. 
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4.2 EVOLUTION OF PLAQUE MEASUREMENTS 
Early in the 1980’s, a few studies assessed carotid lesions from symptomatic patients who 
underwent a carotid endarterectomy.  Ultrasound measurements were performed before the 
surgery, scored with a subjective scale and compared to the histology reports.(11;18)  In the 
1990’s ultrasound technology improved resolution improving subjective scoring of plaques with 
histology. (6;19;20) Plaque composition was also being studied with invasive and other 
noninvasive technologies such as  angiography, (20) magnetic resonance (MR) imaging,(21-24) 
and spiral CT(25)  Studies were suggesting that hypoechoic carotid plaques were seen more 
often in patients with cerebrovascular symptoms than in those without symptoms.  However, 
standardization and reproducibility remained unresolved issues in the use of these techniques.  In 
the last several years, investigators have moved to commercially available, general image 
assessment software to analyze carotid plaques.(8;26-28) Although these packages were not 
made specifically for evaluating atherosclerotic lesions, they showed promise.  With ultrasound 
and image software, the gray scale median (GSM) values have been used to quantify carotid 
plaque characteristics.  The initial studies reported that lower GSM’s are associated with 
cerebrovascular symptoms and now specialized software is available for plaque characterization.   
Project three of this dissertation implements the use of the software by 1) developing scanning, 
digitizing and reading protocols, 2) training and implementing computer software specifically 
developed to evaluate carotid plaque characteristics, and 3) developing and implementing a pilot 
study to assess the reproducibility of the new measures. 
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4.3 CHARACTERIZING PLAQUES 
The Gray-Weale score (GWS) is a subjective scoring system used specifically to characterize the 
plaques.  A basic understanding of how plaques are described is helpful to be able to understand 
the GWS.  The basic descriptors are as follow: 
Echolucent or hypoechoic = appear black on ultrasound 
Echogenic or hyperechoic = appear white on ultrasound 
Heterogeneous has mixed echogenicity = appear black and white, sometimes calcified 
Homogeneous is uniformly echogenic = either dominantly black, white or gray 
 
The GWS used the above descriptors and assigns a number (1-4) to each plaque 
according to the following guidelines: type 1, dominantly echolucent; (similar to blood) type 2, 
dominantly echolucent with small areas of echogenicity; type 3, substantially echogenic with few 
echolucent spots; or type 4, uniformly echogenic(11) and for this project, a type 5 was added 
meaning, unclassified, due to artifacts or poor image quality.  These will be described in more 
detail in the training section of this dissertation.  
To improve plaque characterization research, the tests must be 1) valid 2) standardized 
and 3) reproducible.  Computerized software is the logical choice to improve plaque assessment 
and it meets these criteria.  In most image assessment programs, no mechanism exists to deal 
with sources of error such as artifacts, commonly seen on carotid ultrasound images.  The 
software used in this project reduces error due to artifacts and partnered with carotid ultrasound,  
carotid plaque assessment may be a promising methodology to characterize plaques. 
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4.4 DEPARTMENT OF EPIDEMIOLOGY ULTRASOUND RESEARCH 
LABORATORY (URL) 
The Ultrasound Research Laboratory (URL) at the University of Pittsburgh, has been performing 
carotid ultrasound in epidemiological studies since 1985, beginning with the Systolic 
Hypertension in the Elderly Program (SHEP) and the Cardiovascular Health Study (CHS).  The 
Laboratory (URL) was established with the goal of providing a high volume of quality 
ultrasound studies for research purposes. Staffing includes three full-time registered vascular 
technologists, and two part-time technologists who read studies and provide additional support. 
The technologists are trained and certified in all testing procedures provided by the laboratory.  
The lab supports 13 ongoing studies funded by the NIH, the American Heart Association and the 
National Arthritis Foundation.  In 2005, our total test volume was 1710 tests on 1100 
participants. 
The laboratory offers subclinical atherosclerosis measures using carotid ultrasound 
technology that focuses on intima media thickness (IMT) a well established subclinical measure. 
In the past identification of plaques was adequate but in light of newer research, more specific 
plaque assessment would benefit the studies.  Thus, to add a measure of plaque characterization 
to the capabilities of the URL would improve research methods.  We believe the addition of 
plaque assessment will lead to better assessment of CV risk and improve preventative and 
treatment of patients.  
62 
4.5 FINAL OVERVIEW OF PROJECT THREE 
Better prevention is needed to identify people at risk for cardiovascular disease who are 
asymptomatic.  Past research has provided the first steps into effective CVD prevention and 
mortality reduction with IMT measures. Yet, new risk assessment tools need to be developed 
since half of all heart attacks occur in individuals with normal risk factor levels. The study of 
plaques in vivo has emerged as a promising avenue to further identify at-risk patients for CV 
events.  This project proposes to use the various subclinical atherosclerotic measures to assess 
two high risk populations and to develop protocols for a novel tool used to characterize carotid 
plaques.  Successful use of this new tool will allow improved plaque assessment in clinical trials 
and move ultimately improve CVD prevention efforts.  
 A summary of the data collection that will yield analysis for a final assessment 
will result in the following measures for plaque analysis: 
1. Gray-Weale Scale (GWS) (subjective measure) 
2. Gray Scale Median (GSM) (quantitative measure) 
3. Calcification prevelance 
4. Echocucent vs. echogenic (based on computerized quantitative measure %WHITE) 
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4.6 ULTRASOUND INSTRUMENTATION 
High resolution ultrasound (US) machines are used to obtain quality images for research 
purposes.  Ultrasound transducers contain piezoelectric crystals that convert pressure waves into 
electrical signals and go through complex algorithms to display images on a monitor.  
Simplistically, the waves are emitted from the transducer into the tissue, and bounce back with 
varying degrees of intensity based on tissue density.  The machine measures the intensity and an 
image is displayed using 255 shades of gray on a television-like monitor.  Blood density, for 
example, is displayed with black pixels and soft tissue has varying degrees of black pixels that 
appear white or shades of gray.(Figure 4-1)  This image is called the grayscale image or B-mode 
image (Brightness mode).  
 
 
 
 
 
 
 
 
 
 
Figure 4-1 Different pixel intensities as tissue density changes 
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4.7 METHODS 
Scanning Protocol 
The participant is placed supine with the knees supported and the sonographer at the head of the 
bed.  A standard lead II electrocardiogram rhythm is gathered throughout the exam.  The carotid 
system is imaged from the base of the neck to the most cephalad portion possible.  The regions 
of interest include the distal common carotid artery, the carotid bifurcation and the internal 
carotid artery (Figure 4-2)  A carotid artery plaque is defined as a focal projection into the lumen 
that is 50% or greater than adjacent wall thickness or a thickness of >1.5mm.  The sonographer 
completes the plaque worksheet as each segment or side is scanned.(Appendix D) The image 
containing the plaque is optimized using hand movements, time-gain-compensation, and head 
maneuvers until the full plaque is seen with intact shoulders.  A cineloop (memory) is captured 
and replayed frame-by-frame.  The optimum image is digitized in end diastole and saved for off-
line scoring at a later time.  One challenge for plaque assessment is to optimize the entire plaque 
for digitization while clearly displaying the interfaces.  The shoulders are the areas before and 
after the plaque that attach to the intima-media surfaces and should be well visualized.  (Figure 
4-3) 
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Figure 4-2: Schematic of carotid artery 
Section 1,  from the origin of the common carotid artery (CCA) to 2 cm proximal to carotid 
bifurcation; 2, from 2 cm proximal to carotid bifurcation to beginning of carotid bifurcation 
bifurcation (point where the near and far walls of artery are no longer parallel); 3, from 
beginning of carotid bifurcation to flow divider; 4, first centimeter of internal carotid artery 
(ICA), measured from tip of flow divider; 5, first centimeter of external carotid artery (ECA), 
measured from tip of flow divider 
 
 
 
 
 
 
 
 
 
Figure 4-3:  Plaque Shoulders 
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4.8 READING PROTOCOL 
The image is imported into the Automated Measurement Software (AMS, Sweden) and 
calibrated to set the range of gray scale specific for that image.  Calibration is accomplished by 
selecting an area that is black (anechoic) (typically within the lumen) and a second area that is 
the white (echoic), such as the adventitia. The software sets the scale with these two measures 
which is then used to assign the gray scale intensity for each pixel within the plaque.  The reader 
zooms the image, outlines the plaque along the lumen-intima interface and along the media-
adventitia interface.  The plaque ends are identified where the plaque becomes 50% of the 
adjacent IMT and the region of interest is closed with vertical lines at each end.  The plaque is 
now encapsulated and ready for assessment.  The software is then prompted to assess each pixel 
within the plaque based on the initial scale and values are produced using complex algorithms. 
The quantitative scores are determined electronically and reported as percent white and gray 
scale median.  Also, a descriptive (echogenic vs. echolucent) score is assigned based on the 
quantitative data.   The reader also subjectively scores the plaque just prior to the software 
scoring.  The full technical step-by-step protocol is in Appendix B.  
The automated outcome measures generated by the software are 1) the gray scale median 
(GSM), 2) the percent white value and 3) plaque classification.  The GSM and percent white 
values are continuous variables and the plaque classification is a binomial variable. 
4.9 SOFTWARE CONSIDERATIONS 
The AMS software is different than the conventional image software being used for research 
currently.  These software use the normalized mean intensity but this does not work properly 
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because of the two types of artifacts seen with ultrasound.  Based on an analysis of the 
distribution of pixel intensities inside the plaque, a grayscale threshold is automatically selected 
so that the plaque is segmented into white and dark points (a so called binary plaque image). 
The percentage of white pixels is calculated and used as a feature for classifying the 
plaque as being echolucent (low percentage of white) or echogenic (high percentage of white). 
The classification of plaque into echolucent and echogenic is based on a detailed analysis of the 
pixel intensities inside and outside the plaque.  There are three different aspects of this analysis. 
The first aspect concerns the percentage of "white" pixels inside the plaque.  On ultrasound, 
noise is represented by snow that can be within the lumen and also within the plaque. The AMS 
software compensates for this artifact by "removing" the snow. 
The second aspect concerns a measure of white artifacts inside the lumen, similar to the 
noise described above.  The underlying idea is to compensate for this type of artifact.   In short, if 
the plaque contains the same type of white artifacts as inside the lumen, it should not be taken 
into account in the calculation of percentage of white. 
The third aspect concerns shadows under the plaque. If those shadows are caused by 
bright reflectors inside the plaque, the dark part inside the plaque and under the reflector should 
not be included in the calculation of percentage of white.  The AMS software also compensates 
for this by "removing" the shadows.  By eliminating these errors, the percent white value is more 
robust than using the gray scale median. 
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4.10 TRAINING AND CERTIFICATION 
Image Capture 
Image quality is of utmost priority when performing subclinical atherosclerosis measures with 
ultrasound.  Images must be clear, showing continuous interfaces and distinct plaques. Gains 
must be carefully adjusted for each image to avoid missing any plaques and to prevent artifacts 
that can be mistaken for plaques.  Hand maneuvers to that assure excellent images are not 
intuitive and must be taught, practiced and perfected.  We changed our protocol to capture 
plaque images with clear interfaces and adequate distinct shoulders.  While implementing this 
change, we reviewed captured images during the learning process until the staff was proficient 
acquiring plaque images.  Over an eight month period the staff collected images of all plaques 
from any research study participant tested in the lab.  The standard research protocol was used 
with the addition of digitized images of all plaques on each scan. 
 
Subjective Plaque Scoring (Gray Weale Scale) 
Plaque scoring involves two separate processes: subjective scoring and electronic scoring.  I 
started with subjective scoring as a first step to understand plaque characterisitics.  For that we 
used the Gray-Weale scoring system.  Training included several sessions of didactic training and 
review of many sample images.   
We adopted the GWS that includes the standard four categories and added a fifth 
category to indicate that the image was not able to be scored due to artifacts.  Category 1 of the 
GWS was a plaque that is mostly echolucent, appearing mostly black (Figure 4-4) on ultrasound 
exam.  Category 2 represents a plaque that is heterogeneous, consisting of more echolucency 
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than echogenicity (Figure 4-5).  Category 3 represents a plaque that is also heterogeneous, but 
consists mostly of echogenic material and has less than 25% echolucent areas within it (Figure 
4-6)  Category 4 represents a plaque that appears mostly echogenic (Figure 4-7).  Category 5 is a 
plaque that cannot be categorized due to shadowing.  
 
 
Figure 4-4: Schematic of plaque, category 1 of the Gray-Weale Scale.  The plaque is mostly echolucent.   
For corresponding ultrasound image: Figure 4-8 
 
 
 
Figure 4-5: Schematic of plaque, category 2 of the Gray-Weale Scale.  The plaque is heterogenous 
and mostly echolucent with some echogenic material.  For corresponding ultrasound image:Figure 4-9
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Figure 4-6: Schematic of plaque, category 3 of the Gray-Weale Scale.  The plaque is mostly echogenic 
with <25% of echolucency.  For corresponding ultrasound image:  Figure 4-10 
 
Figure 4-7: Schematic of plaque, category 4 of the Gray-Weale Scale.  The plaque is mostly echolucent.  
For corresponding ultrasound image:  Figure 4-11 
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Figure 4-8:  Category 1 of GWS:  Echolucent plaque. Plaque would not be visible without high gains 
 
 
 
 
 
 
 
 
 
 
 
Figure 4-9:  Category 2 of GWS:  Mostly echogenic (white) but has less than 25% of echolucency
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Figure 4-10:  Category 3 of the GWS:   Mostly echogenic with a small amount of echolucency 
 
 
 
 
Figure 4-11:  Category 4 of the GWS: Mostly echogenic. Notice the shadowing which indicates calcification. 
 
 
After several training and practice sessions the two certified sonographers read several different 
groups of plaque images and the percent agreement was assessed.  After reading each group, the 
staff met regularly to discuss their results and problems they faced.  These meetings and ongoing 
scoring improved agreement over time from 27% to 77% (Table 4-1) over an 8 month period.   
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Table 4-1:  Project 3 Percent agreement of GWS between readers over 8 month training period 
Group Number 
Agreed 
Number of 
Images 
Percent 
Agreement 
1 4 15 27% 
2 7 15 47% 
3 9 13 69% 
4 8 11 73% 
5 16 28 57% 
6 23 30 77% 
 
4.11 AUTOMATED PLAQUE CHARACTERIZATION 
Automated plaque assessment training was performed in several phases.  I obtained the software 
and was self-trained by reading the manual and experimentation.  While experimenting I used 
email to pose questions to the developers.  After I was familiar with the software and practiced 
reading images, I had two telephone calls with the developer to answer additional questions, 
discuss problems I encountered, and review the results.  I wrote and standardized the capturing 
and reading protocols and then trained the staff on these protocols. 
To standardize plaque length I decided at what point the increase in IMT became plaque 
and this was used as the longitudinal plaque endpoints.  We standardized closing the region of 
interest with vertical lines at each end of the plaque. Last, we standardized the posterior portion 
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of the ROI to be as close to the pixel above the hyperechoic demarcation of the adventitial border 
(Figure 4-12)  
 
 
 
 
 
 
 
 
 
 
 
Figure 4-12:   Selection of plaque region of interest 
4.12 REPRODUCIBILITY OF PLAQUE MEASURES 
A pilot study to assess the reproducibility of the automated plaque assessment between readers 
was executed (see Appendix G).  The automated reading was performed on the same 50 plaque 
images by three readers.  Two were full-time certified sonographers and one was a 
nonsonographer but trained in subclinical methodology.  Both the sonographer and 
nonsonographer repeatability was tested to see whether a specially trained sonographer was 
required to read plaque images.  The results were analyzed to test agreement between the 
readers.  Briefly, spearman correlation was assessed for the gray-scale median and the percent 
Ends of plaque are closed with 
a vertical closure. 
The back wall of the plaque is 
selected just above the 
hyperechoic adventitial 
demarcation.  
 
The plaque begins when 
the plaque is 
approximately 1.5 times 
thicker than the IMT. 
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white variable.  Comparison of the two full-time sonographers yielded a Pearson correlation of 
the GSM 0.88. The intraclass correlation (ICC) showed that 86% of the variation in GSM is due 
to the differences between participants.  For the more robust percent white variable, the Pearson 
correlation was 0.89 with 89% of the variable due to the difference between participants.  The 
subjective Gray-Weale scores correlated 82% of the time.  The kappa statistic for between 
readers for the automated plaque categorization was 0.61, which represents good agreement.  
After analysis, the readers reviewed each image and discussed problems they 
experienced.  As a group, we discussed the differences in reading and I conducted remedial 
training to further standardize the protocol.  During this training, we discovered several ways to 
standardize the technique to improve replication.  First, the plaque images were not consistently 
zoomed before encapsulating the plaque for analysis.  We now require the images to be zoomed 
to see the plaque borders more clearly.  Second, the media-adventitia line was sometimes drawn 
one pixel inside the medial border and other times it was drawn one pixel outside the medial 
border, thus including the adventitial wall.  When the latter was done, the percent white value 
was erroneously higher.  After analyzing how this affected one of the main outcome measures 
(percent white), we decided to draw the media-adventitia line of the plaque, just inside the 
medial border, thus avoiding a false increase in the percent white value, by including the pixels 
from the adventitial interface.  The third change was when the user selected the region of interest 
for setting the threshold value.  Some users used a large box while others made a small box, just 
large enough to include the vessel and plaque.  The software developers recommended using the 
largest box possible to improve setting the threshold value, based on the algorithms.  We 
standardized each of these steps and the two full-time sonographers plan to reread the same 50 
images.  
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The automated software improved the agreement between readers for the plaque 
categorization 87% vs. 27% when the staff categorized the plaques.  The percent white 
quantification is slightly more robust than the grayscale median. 
The tentative goals for plaque reproducibility are: ≥ 90 for both Pearson correlation and 
the intraclass correlation for the GSM and percent white measures.  A Kappa statistic of >.75 
will be the tentative goal for the automated computerized classification for plaques.  This value 
represents excellent agreement.(29) 
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4.13 QUALITY CONTROL 
Quality control (QC) processes help prevent minor drifts in scanning and reading techniques that 
have been known to jeopardize image quality and progression data.  QC is an essential 
component of any research facility and the URL has several processes setup.  First we assess the 
scanning process by one sonographer over scanning five participants for all the other 
sonographers on a quarterly basis. A constant reader reads all images.  We can evaluate if any 
plaques are missing and if the plaque characterization is similar.  As a second piece of QC we 
review the tapes of 10 scans quarterly and give direct feedback to the sonographers regarding 
plaque identification and protocol adherence. 
Sonographers are recertified yearly for both scanning and reading.  All sonographers scan 
the same participants and each sonographer reads all the images which allows between 
sonographer correlations as well as between reader correlations for all measures.  
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5 WORK TO BE DONE AFTER FINAL DEFENSE 
Several goals are planned for the next year.  First, the remaining 50 images will be read to 
complete a reproducibility analysis between and within reader (total N=100).  I plan to publish 
these results after the software developers publish the validity study for the plaque module of the 
AMS software.  
 Second, I plan to include plaque assessment in several upcoming grants.  One study is in 
a population of women with systemic lupus erythematosus (SLE).  A comparison of plaque 
composition between women with SLE and controls may identify different plaque characteristics 
in SLE women, helping to understand why their CVD risk is so high.  The draft proposal for this 
grant is included in this dissertation (see Appendix H).   
 In the URL, we also plan to assess the relationship of plaque characteristics with 
cardiovascular risk factors in other populations.  I plan to write a grant to fund this work.  We 
also have the potential to evaluate plaques in different diseased populations as we educate other 
investigators about this new methodology. 
 The URL provides ultrasound tests on ongoing research projects of many populations and 
providing plaque assessment to study subclinical cardiovascular disease will expand our 
knowledge of plaque morphology.  
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APPENDIX A:  PLAQUE ASSESSMENT TECHNICAL PROTOCOL 
Date:  02/2006 
Software: AMS Plaque Assessment Module 
Note:  This protocol is for vascular sonographers familiar with reading IMT 
images 
Software: AMS Plaque Assessment Module 
 
Step by step process: 
1. Open Plaque Assessment Software 
2. Select the image to be analyzed:  
a. File… load image… select the image to be read 
3. To calibrate the image…Click on CALIBRATE. Click the left mouse button on a 
measurement tick  typically on the side of the image. This sets the first tick. If you 
need to move it, use the up/down arrows for proper placement.  
a. To set the second cursor repeat the same process on the tick that indicates 1 cm 
b. Click OK to finish the calibration process 
4. Set Reference points: This is how the computer will know the range of gray scale for 
this particular image.  
5. Set gray scale range:  
a. Click BLACK… You will now select a part of the US image that is the blackest.  
The lumen should be the backest part of the image.  Move the mouse cursor to the 
lumen and click once with the left mouse and drag to make a small region of 
interest (ROI) box. This sets the scale to the blackest pixels.  At the top of the 
screen the black reference is seen.  
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b. Click WHITE… move mouse cursor to the adventitia and click once with the left 
mouse and drag to make a small region of interest (ROI) box on the whitest area 
of adventitia. This sets the scale to the whitest pixels. (Figure 5-1) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5-1:  Black and white reference values for plaque characterization. 
 
6. Select the area on the screen that is ultrasound data:  
a. Select IMAGE… Draw a box around the portion of the picture that contains 
ultrasound data. Be sure to exclude any words and EGG.  Keep the borders inside 
the image a little bit so you don’t accidentally select non-ultrasound data. 
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7. Prepare to score the first plaque 
a. Select ADD under PLAQUE.  The first plaque will appear in writing in the box. 
Using the left mouse button, outline the plaque. Stop the ends where the IMT is 
about 50% of the adjacent ‘reference ‘ IMT.  
8. Subjectively score the plaque 
a. Click on CLASS drop-down arrow and select the Gray-Weale score that you think 
applies to this plaque.  
9. Score the plaque electronically 
a. Click on CLASSIFY and the system will score the plaque. It will assign either 
echogenic or echolucent to describe the plaque.   
10. Save the data 
a. Select FILE… SAVE PLAQUE 
11. View the results  
a. select RESULTS (at the top) … VIEW RESULTS 
b. A window will open. To view all the results, double click on the blue icon to the 
left of the data lines. This will expand the subdirectory.  
c. Locate the line that begins with FEATURES.  The main values of interest for 
plaque assessment are the percent WHITE value and the MEDIAN. (Figure 5-2) 
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Figure 5-2:  Main values of interest in output window for plaque assessment. 
 
 
 
 
 
83 
APPENDIX B:  GRAY-WEALE SCALE SCORING PROTOCOL 
1.  Assess each image individually for the following 
• Is there a plaque?  Confirm its presence in at least 2 projections.  A plaque is 
defined as an area that is greater than the adjacent IMT by 50 %.  
• Capture the plaque displaying the shoulders. The shoulder is where the plaque 
begins and ends and is connected to the intima-medial segment. The plaque 
should be continuous as shown in figure 3-5.  
 
Figure 5-3: The shoulders of a plaque 
 
 
 
 
 
 
• Assess the vessel lumen for echos.  The lumen should be the blackest area of the image if 
the gains are set properly. Sometimes if the plaque is hypoechoic the sonographer needs 
to increase the gains to see the plaque.  This is the case in the image above. The plaque 
was hypoechoic and the sonographer increased the gains to clearly display the plaque. 
The reader can assess this because the lumen has artifacts within it.  If the gains are 
reduced completely to blacken the lumen, it is likely that the plaque would be difficult to 
see or may disappear entirely. This is important when assigning the GWS.  If the gains 
need to be elevated to see the plaque, the plaque is likely more black than the image is 
reflecting.  The reader may choose to drop the score down by 1 category in this case.  
• Assess the plaque according to the following scale guidelines: 
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Type 1: dominantly echolucent (black), similar to blood (lumen) 
Type 2:  dominantly echolucent with small areas of echogenicity 
Type 3:  substantially echogenic with few echolucent (black) spots 
Type 4:  uniformly echogenic 
Type 5:  unclassified due to dense calcification and shadowing or unable to see 
whole plaque. (shoulders are missing, some other technical problem) 
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APPENDIX C:  DUPLEX SCAN PLAQUE ASSESSMENT WORKSHEET 
 
Study __________ 
 
Record#_______________________ 
 
URL ID:______________________ 
 
Enter:_________________________ 
 
Study ID:_____________________ 
 
Vertify:______________________ 
 
Scan Date_____/_____/__ __ __ __  
 
Scan Category:___________ 
 
Reader:_________ Read date: 
_________ 
 
Repro only: Scan Seq: _______ Read Seq 
 
A. Plaque: 
Right CCA Artery  FW    NW  No plaque   Thickening  
____ 1: Dominantly echolucent plaques, with a thin echogenic cap 
____ 2: Substantially echolucent lesion with small areas of echogenicity 
____ 3: Dominantly echogenic lesions with small areas of echolucency (<25%) 
____ 4: Uniformly echogenic lesion 
___  5: Unclassified due to dense calcification and shadowing or no shoulder 
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Right BIFURCATION  FW    NW  No plaque   Thickening  
____ 1: Dominantly echolucent plaques, with a thin echogenic cap 
____ 2: Substantially echolucent lesion with small areas of echogenicity 
____ 3: Dominantly echogenic lesions with small areas of echolucency (<25%) 
____ 4: Uniformly echogenic lesion 
___  5: Unclassified due to dense calcification and shadowing or no shoulder 
 
 
Right ICA Artery  FW    NW  No plaque   Thickening  
____ 1: Dominantly echolucent plaques, with a thin echogenic cap 
____ 2: Substantially echolucent lesion with small areas of echogenicity 
____ 3: Dominantly echogenic lesions with small areas of echolucency (<25%) 
____ 4: Uniformly echogenic lesion 
___  5: Unclassified due to dense calcification and shadowing or no shoulder 
URLID: _______________ 
 
A. Plaque – Left CCA Artery  FW    NW  No plaque   Thickening  
 
____ 1: Dominantly echolucent plaques, with a thin echogenic cap 
____ 2: Substantially echolucent lesion with small areas of echogenicity 
____ 3: Dominantly echogenic lesions with small areas of echolucency (<25%) 
____ 4: Uniformly echogenic lesion 
___  5: Unclassified due to dense calcification and shadowing or no shoulder 
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 Left BIFURCATION  FW    NW  No plaque   Thickening  
____ 1: Dominantly echolucent plaques, with a thin echogenic cap 
____ 2: Substantially echolucent lesion with small areas of echogenicity 
____ 3: Dominantly echogenic lesions with small areas of echolucency (<25%) 
____ 4: Uniformly echogenic lesion 
___  5: Unclassified due to dense calcification and shadowing or no shoulder 
 
 
Left ICA Artery  FW    NW  No plaque   Thickening  
____ 1: Dominantly echolucent plaques, with a thin echogenic cap 
____ 2: Substantially echolucent lesion with small areas of echogenicity 
____ 3: Dominantly echogenic lesions with small areas of echolucency (<25%) 
____ 4: Uniformly echogenic lesion 
___  5: Unclassified due to dense calcification and shadowing or no shoulder 
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APPENDIX D:  PLAQUE CHARACTERIZATION FULL REPORT 
N=50 
 
 
 
 
 
 
 
 
 
 
 
 
 
Ultrasound Research Laboratory 
 
Planned, Trained, Implemented, Analyzed and Interpreted  
 
By 
 
Trina Thompson MPH, BSN, RVT 
February 20, 2006 
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D.1.1 Plaque Characterization using AMS Reproducibility Analysis 
Between readers 
02/15/06 
Purpose: 
The purpose of this analysis was to assess the interreader repeatability of several values during 
plaque characterization using the AMS plaque module.  
 
Sample: 50 images were collected from any study in the URL. These images reside at:  
U:\URL\Plaque_repro_for LUPUS_grant_01_2006  
Variables of primary interest:  
 Gray scale median  Percent White of ‘feature’ (plaque) 
Other variables compared: 
 Black reference value 
 White reference value 
 Area of plaque 
 
Statistical Analysis: 
Correlation analysis between PWV Read1 and Read2 was carried out using Spearman rank 
correlation. Repeatability of the 2 measures was assessed using the method described by Bland and 
Altman (1). Limits of agreement were calculated using a regression approach for nonuniform differences 
between measures recommended by the same authors (2). Additionally the variance component 
(VARCOMP) procedure in SAS was utilized to calculate the intraclass correlation coefficient of 
reliability. 
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D.1.2 Summary of Results: 
Descriptive Statistics: 
Measure 
N=50 
Reader 06 Reader 023 Reader 049 
 Mean Range Mean Range Mean Range 
GSM 57 (18) 26 - 95 51.8 (16.7) 27 - 91 55.3 (17.7) 29 - 103 
% White 36 (18) 5 - 74 33.9 (17.3) 2 - 71 36.9 (15.9) 3 - 76 
Mean 65 (18) 30 - 101 59.6 (17.0) 30 - 95 64.5 (18.5) 38 - 113 
Black Ref 8.5 (11.3) 0 - 74 8.6 (11.2) 0 - 74 9 (11) 1 - 74 
White Ref 199 (46) 97 - 255 205.2 (44.1) 112 - 255 207 (45) 112 - 255 
Area 20 (10.7) 6 - 48 17.7 (7.4) 3.7 – 35.9 21 (10) 5 - 46 
Differences 049-006 049-023 Eventually 049-049 
GSM -2.1 (10.9) -25 - 19 3.5 (8.6) -14 - 24   
% White 0.9 (7.9) -19 - 23 3.0 (7.8) -13 - 18   
Mean -0.6 (12.5) -27 - 25 4.9 (10.7) -23 - 29   
Black Ref 0.6 (1.5) -2 - 5 0.54 (1.4) -2 - 5   
White Ref 8.7 (17.9) -28 - 62 2. (11.9) -21 - 45   
Area 0.7 (7.8) -25 - 16 3. (5.4) -7 - 16   
Spearman 
Corr GSM 
0.79 0.84   
Pearson Corr 
GSM 
0.82 0.88   
ICC GSM 0.82 0.86   
Spearman 
Corr % White 
0.86 0.85   
Pearson Corr 
% White 
0.89 0.89   
ICC % White 0.89 0.89   
Kappa 
Automated 
Class 
0.61 0.41   
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GSM 
Random difference checks Tonee(49) – Dennis (23) = gsmdiffTD 19 (-‘s)= 38% 
                                                                     gsmdiff 
                    Obs              ID    plqgsm049    plqgsm023       TD 
                      1              30        63           77         -14 
                      2              18        39           52         -13 
                      3              37        38           50         -12 
                      4              19        39           48          -9 
                      5              21        32           39          -7 
                      6              12        46           52          -6 
                      7              38        75           81          -6 
                      8               9        38           43          -5 
                      9              43        51           56          -5 
                     10              50        60           65          -5 
                     11              17        53           57          -4 
                     12              20        41           45          -4 
                     13              41        37           40          -3 
                     14              22        67           69          -2 
                     15              33        77           79          -2 
                     16              15        29           30          -1 
                     17              23        38           39          -1 
                     18              28        65           66          -1 
                     19              46        88           89          -1 
                     20              49        68           68           0 
                     21              29        37           36           1 
                     22              44        67           65           2 
                     23              31        40           37           3 
                     24              48        36           33           3 
                     25              27        95           91           4 
                     26              35        38           34           4 
                     27              42        31           27           4 
                     28               1        42           37           5 
                     29               6        47           42           5 
                     30               3        63           57           6 
                     31               7        43           37           6 
                     32               8        71           64           7 
                     33              13        41           34           7 
                     34              16        45           38           7 
                     35              39        65           58           7 
                     36              34        94           86           8 
                     37              32        54           44          10 
                     38               2        50           39          11 
                     39              10        63           52          11 
                     40              36        50           39          11 
                     41               5        52           40          12 
                     42              25        46           34          12 
                     43              45        58           46          12 
                     44              11        69           56          13 
                     45              24        69           56          13 
                     46              14        57           43          14 
                     47               4        54           39          15 
                     48              26        59           43          16 
                     49              40        80           59          21 
                     50              47       103           79          24 
SPEARMAN CORR Procedure GSM 
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N=50 
 
                         2  Variables:    plqgsm049 plqgsm023 
 
  Variable   N          Mean    Std Dev     Median     Minimum       Maximum 
 
plqgsm049       50    55.26000   17.70831   52.50000   29.00000     103.00000 
plqgsm023      50     51.80000   16.65251   47.00000   27.00000      91.00000 
 
 
                           Spearman Correlation Coefficients, N = 50 
                                   Prob > |r| under H0: Rho=0 
 
                                           plqgsm049      plqgsm023 
 
                            plqgsm049        1.00000        0.84284 
                                                             <.0001 
 
                            plqgsm023        0.84284        1.00000 
                                              <.0001 
 
 
Spearman correlation between Tonee and Dennis is 0.84 
p-value <0.0001  
Pearson correlation is: 0.88  
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Intraclass correlation between Tonee and Dennis GSM 
 
                            Variance Components Estimation Procedure 
 
                                    Class Level Information 
 
Class       Levels  Values 
 
id               50  1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 
22 23    24 25 26 27 28 
                    29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 
48 49 50 
 
tech             2  23 49 
 
 
                                 Number of observations    100 
 
 
                                 Dependent Variable:    PlqGSM 
 
 
                                  Type 1 Analysis of Variance 
 
                                Sum of 
 Source               DF       Squares   Mean Square  Expected Mean Square 
 
 tech                  1    299.290000    299.290000  Var(Error) + 50 
Var(tech) 
 id                   49         27143    553.947143  Var(Error) + 2 Var(id) 
 Error                49   1810.210000     36.943061  Var(Error) 
 Corrected Total      99         29253             .  . 
 
 
                                        Type 1 Estimates 
 
                               Variance Component        Estimate 
 
                               Var(tech)                  5.24694 
                               Var(id)                  258.50204 
                               Var(Error)                36.94306 
 
Intraclass correlation:  
ICC=var GSM between participants / Total variability= 258.50204 . 300.69203=0.86 
 
Conclusion:  
86% of the variation is GSM was due to differences between participants.  
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Bland Altman 
Tonee (049) and Dennis (023), GSMDIFF 
 
Normality of differences for GSMdiff between Tonee and Dennis 35 
 
                                       The REG Procedure 
                                         Model: MODEL1 
                                 Dependent Variable: gsmdiffTD 
 
                                      Analysis of Variance 
 
                                 Sum of           Mean 
         Source         DF        Squares         Square    F Value    Pr > F 
 
        Model           1       58.20810       58.20810       0.78    0.3802 
        Error           48     3562.21190       74.21275 
    Corrected Total     49     3620.42000 
 
 
                      Root MSE              8.61468    R-Square     0.0161 
                      Dependent Mean        3.46000    Adj R-Sq    -0.0044 
                      Coeff Var           248.97925 
                                      Parameter Estimates 
 
                                                    Parameter      Standard 
Variable    Label            DF      Estimate         Error   t Value   Pr > 
|t| 
 
Intercept   Intercept         1      -0.04568       4.14164   -0.01    0.9912 
meangsmTD   the mean of the GWM    1  0.06549        0.07395   0.89    0.3802 
            of tonee and dennis for BA 
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Percent White 
Random difference checks Tonee – Dennis = pwhdiffTD  17 (-‘s)= 34% 
                                                                   pwhdiff 
                  Obs              ID    plqpwh049    plqpwh023       TD 
                    1              30      26.201       38.814     -12.613 
                    2              28      45.074       56.319     -11.245 
                    3              38      40.951       52.026     -11.075 
                    4              37      34.705       42.761      -8.056 
                    5              50      38.890       45.930      -7.040 
                    6              18      28.714       34.321      -5.607 
                    7              22      49.757       54.743      -4.986 
                    8              12      29.927       34.883      -4.956 
                    9               9      32.444       37.004      -4.560 
                   10              43      34.288       37.870      -3.582 
                   11              49      66.882       70.265      -3.383 
                   12              23      32.100       34.887      -2.787 
                   13              33      47.734       50.280      -2.546 
                   14              21      23.947       26.371      -2.424 
                   15              19      18.480       20.744      -2.264 
                   16              20      20.847       22.841      -1.994 
                   17              34      65.000       65.622      -0.622 
                   18              46      62.602       62.429       0.173 
                   19              31      26.411       25.449       0.962 
                   20              10      45.814       44.842       0.972 
                   21              48       3.311        2.335       0.976 
                   22              41      17.212       16.131       1.081 
                   23              25      13.507       11.914       1.593 
                   24              29      28.105       26.449       1.656 
                   25               6      36.859       35.040       1.819 
                   26              44      45.999       44.155       1.844 
                   27               1      32.145       29.695       2.450 
                   28               8      57.088       53.855       3.233 
                   29              15      11.853        8.464       3.389 
                   30              17      28.519       24.698       3.821 
                   31              35      16.658       12.479       4.179 
                   32              47      72.802       68.441       4.361 
                   33              27      76.229       71.013       5.216 
                   34               7      19.896       13.945       5.951 
                   35              16      32.743       24.250       8.493 
                   36               2      31.641       22.650       8.991 
                   37               3      50.432       41.391       9.041 
                   38              42      21.655       12.340       9.315 
                   39              40      52.700       43.364       9.336 
                   40              11      38.945       29.140       9.805 
                   41               5      32.168       21.543      10.625 
                   42              14      46.361       34.403      11.958 
                   43              13      41.296       29.224      12.072 
                   44              26      44.249       31.917      12.332 
                   45              32      19.922        5.070      14.852 
                   46               4      37.093       21.668      15.425 
                   47              45      38.313       22.400      15.913 
                   48              24      54.250       38.325      15.925 
                   49              39      43.465       27.199      16.266 
                   50              36      31.112       13.571      17.541 
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The CORR Procedure 
1 With Variables:    plqpwh023 
1      Variables:    plqpwh049 
Tonee and Dennis 
 
 
Simple Statistics 
 
  Variable     N   Mean     Std Dev       Median       Minimum       Maximum 
 
  plqpwh023   50  33.90940  17.29075      33.11900      2.33500      71.01300 
  plqpwh049   50  36.94592    15.91481     34.49650       3.31100    76.22900 
 
 
                           Spearman Correlation Coefficients, N = 50 
                                   Prob > |r| under H0: Rho=0 
 
                                                   plqpwh049 
 
                                    plqpwh023        0.84509 
                                                      <.0001 
 
Spearman correlation between Tonee and Dennis is 0.85 
p-value <0.0001  
Pearson correlation is: 0.89 
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ICC for Tonee and Dennis 
Percent White variable 
                            Variance Components Estimation Procedure 
 
                                    Class Level Information 
 
Class       Levels  Values 
 
id              50  1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 
23 24 25 26 27 28 
                    29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 
48 49 50 
 
tech             2  23 49 
 
                                 Number of observations    100 
                                 Dependent Variable:    PlqPWh 
 
                                  Type 1 Analysis of Variance 
 
                        Sum of 
 Source           DF       Squares   Mean Square  Expected Mean Square 
 
 tech              1    230.511343    230.511343  Var(Error) + 50 Var(tech) 
 id               49         25575    521.935641  Var(Error) + 2 Var(id) 
 Error            49   1485.456400     30.315437  Var(Error) 
 Corrected Total  99         27291             .  . 
 
 
                                        Type 1 Estimates 
 
                               Variance Component        Estimate 
 
                               Var(tech)                  4.00392 
                               Var(id)                  245.81010 
                               Var(Error)                30.31544 
 
Intraclass correlation:  
89% of the variation of ‘% white’ was due to differences between participants.  
Math: 
ICC=var ‘% white’ between participants / Total variability= 245.81010/280.12946=0.89 
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Bland-Altman 
Tonee and Dennis Percent White DIFF 
Normality for Percent White Diff  between Tonee and Dennis 
 
                                       The REG Procedure 
                                         Model: MODEL1 
                                 Dependent Variable: pwhdiffTD 
 
                                      Analysis of Variance 
 
                                             Sum of           Mean 
Source           DF        Squares         Square    F Value    Pr > F 
 
Model             1       97.98715       97.98715       1.64    0.2069 
Error            48     2872.92565       59.85262 
Corrected Total  49     2970.91280 
 
                      Root MSE              7.73645    R-Square     0.0330 
                      Dependent Mean        3.03652    Adj R-Sq     0.0128 
                      Coeff Var           254.78006 
 
                             Parameter Estimates 
 
                                     Parameter      Standard 
Variable    Label            DF      Estimate       Error   t Value   Pr > 
|t| 
 
Intercept   Intercept        1      6.13776       2.65928      2.31     
0.0253 
meanpwhtd   the mean of      1      -0.08754      0.06841     -1.28     
0.2069 
            the percent white of tonee and dennis for Bland-Altman 
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Kappa Statistic 
Auto_class 
KAPPA 
Tonee and Dennis 
Automated CLASS Variable 
                                    The FREQ Procedure 
 
                                Table of auto_c049 by auto_c023 
 
                             auto_c049     auto_c023 
 
                                    Simple Kappa Coefficient 
                                Kappa                     0.4156 
                                ASE                       0.1615 
                                95% Lower Conf Limit      0.0991 
                                95% Upper Conf Limit      0.7321 
 
                                        Sample Size = 50 
 102 
Analysis between Tonee (49) and Holly (06) GSM 
Very experienced reader vs. minimally experienced reader 
Random difference checks Tonee–Holly=gsmdiffTH  27 (-‘s) = 54% 
                    Obs              ID    plqgsm049    plqgsm06       TH 
                      1               3        63          88         -25 
                      2               9        38          60         -22 
                      3               7        43          64         -21 
                      4               8        71          89         -18 
                      5              24        69          85         -16 
                      6               4        54          69         -15 
                      7              18        39          53         -14 
                      8              22        67          81         -14 
                      9              29        37          50         -13 
                     10              37        38          50         -12 
                     11              38        75          87         -12 
                     12              20        41          51         -10 
                     13              41        37          47         -10 
                     14              49        68          78         -10 
                     15              21        32          41          -9 
                     16              13        41          50          -9 
                     17              48        36          44          -8 
                     18              28        65          72          -7 
                     19              46        88          95          -7 
                     20              35        38          45          -7 
                     21               6        47          52          -5 
                     22              12        46          49          -3 
                     23              43        51          54          -3 
                     24              50        60          63          -3 
                     25              17        53          56          -3 
                     26              23        38          40          -2 
                     27              15        29          30          -1 
                     28              44        67          67           0 
                     29              32        54          54           0 
                     30              16        45          44           1 
                     31              10        63          61           2 
                     32              19        39          36           3 
                     33              27        95          92           3 
                     34              39        65          62           3 
                     35              30        63          59           4 
                     36              40        80          76           4 
                     37              33        77          72           5 
                     38              42        31          26           5 
                     39               1        42          35           7 
                     40              36        50          43           7 
                     41              25        46          38           8 
                     42               5        52          43           9 
                     43              14        57          48           9 
                     44              11        69          57          12 
                     45              26        59          47          12 
                     46              31        40          27          13 
                     47              34        94          80          14 
                     48              45        58          40          18 
                     49              47       103          85          18 
                     50               2        50          31          19 
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SPEARMAN CORR Procedure GSM 
N=50 
Tonne with Holly 
 
                           2  Variables:    plqgsm049 plqgsm06 
 
 
                                       Simple Statistics 
 
  Variable            N          Mean       Std Dev        Median       
Minimum       Maximum 
 
  plqgsm049          50      55.26000      17.70831      52.50000      
29.00000     103.00000 
  plqgsm06           50      57.32000      18.46391      53.50000      
26.00000      95.00000 
 
 
                           Spearman Correlation Coefficients, N = 50 
                                   Prob > |r| under H0: Rho=0 
 
                                            plqgsm049      plqgsm06 
 
                             plqgsm049        1.00000       0.78787 
                                                             <.0001 
 
                             plqgsm06         0.78787       1.00000 
                                               <.0001 
 
 
Spearman correlation between Tonee and Holly is 0.79 
p-value <0.0001  
Pearson correlation is: 0.82 
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Intraclass correlation between Tonee and Holly GSM 
                            Variance Components Estimation Procedure 
 
                                    Class Level Information 
 
Class       Levels  Values 
 
id              50  1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 
23 24 25 26 27 28 
                    29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 
48 49 50 
 
tech             2  6 49 
 
                                 Number of observations    100 
 
 
                                 Dependent Variable:    PlqGSM 
 
 
                                  Type 1 Analysis of Variance 
 
                                Sum of 
 Source               DF       Squares   Mean Square  Expected Mean Square 
 
 tech                  1    106.090000    106.090000  Var(Error) + 50 
Var(tech) 
 id                   49         29155    595.001837  Var(Error) + 2 Var(id) 
 Error                49   2915.410000     59.498163  Var(Error) 
 Corrected Total      99         32177             .  . 
 
 
                                        Type 1 Estimates 
 
                               Variance Component        Estimate 
 
                               Var(tech)                  0.93184 
                               Var(id)                  267.75184 
                               Var(Error)                59.49816 
             328.18184 
 
Intraclass correlation:  
82% of the variation is GSM was due to differences between participants. 
 
ICC=var GSM between participants / Total variability= 267.75184/328.18184=0.82 
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Bland Altman 
Tonee and Holly GSMDIFF 
 
Normality of differences for GSMdiff between Tonee and Holly 
 
                                       The REG Procedure 
                                         Model: MODEL1 
                                 Dependent Variable: gsmdiffTH 
 
                                      Analysis of Variance 
                                   Sum of           Mean 
         Source         DF        Squares         Square    F Value    Pr > F 
         Model           1       30.75994       30.75994       0.25    0.6162 
         Error                    48     5800.06006      120.83458 
         Corrected Total          49     5830.82000 
 
                      Root MSE             10.99248    R-Square     0.0053 
                      Dependent Mean       -2.06000    Adj R-Sq    -0.0154 
                      Coeff Var          -533.61546 
 
                                      Parameter Estimates 
 
                                                    Parameter      Standard 
Variable    Label         DF      Estimate         Error   t Value   Pr > |t| 
 
Intercept   Intercept     1      0.52572        5.35548      0.10     0.9222 
meangsmTH the mean of the GWM  1  -0.04594      0.09104     -0.50     0.6162 
of tonee and Holly for BA 
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Check Difference values for Percent White Variable 
Random difference checks Tonee–Holly = pwhdiffTH 22 (-‘s) = 44% 
 
                    Obs              ID    plqpwh049    plqpwh06       TH 
                      1               7      19.896      38.892     -18.996 
                      2              41      17.212      28.765     -11.553 
                      3               4      37.093      47.220     -10.127 
                      4              38      40.951      50.670      -9.719 
                      5               8      57.088      66.244      -9.156 
                      6               3      50.432      58.600      -8.168 
                      7               6      36.859      44.743      -7.884 
                      8              28      45.074      52.800      -7.726 
                      9              49      66.882      74.089      -7.207 
                     10              12      29.927      37.018      -7.091 
                     11              21      23.947      30.252      -6.305 
                     12              13      41.296      47.543      -6.247 
                     13              50      38.890      43.129      -4.239 
                     14              43      34.288      38.042      -3.754 
                     15              30      26.201      28.467      -2.266 
                     16              37      34.705      36.403      -1.698 
                     17              20      20.847      22.294      -1.447 
                     18              48       3.311       4.685      -1.374 
                     19              22      49.757      51.062      -1.305 
                     20              19      18.480      19.708      -1.228 
                     21               9      32.444      32.782      -0.338 
                     22              46      62.602      62.891      -0.289 
                     23              17      28.519      28.400       0.119 
                     24              35      16.658      16.501       0.157 
                     25              44      45.999      45.759       0.240 
                     26              29      28.105      27.674       0.431 
                     27              24      54.250      53.783       0.467 
                     28              10      45.814      44.924       0.890 
                     29              18      28.714      27.555       1.159 
                     30              33      47.734      46.147       1.587 
                     31              40      52.700      50.974       1.726 
                     32              25      13.507      11.337       2.170 
                     33              15      11.853       8.681       3.172 
                     34              34      65.000      61.479       3.521 
                     35              23      32.100      28.116       3.984 
                     36               5      32.168      27.292       4.876 
                     37               1      32.145      26.363       5.782 
                     38              16      32.743      26.680       6.063 
                     39              27      76.229      69.057       7.172 
                     40              47      72.802      65.278       7.524 
                     41              11      38.945      31.280       7.665 
                     42              14      46.361      38.331       8.030 
                     43              42      21.655      12.390       9.265 
                     44              26      44.249      34.144      10.105 
                     45              31      26.411      15.502      10.909 
                     46              39      43.465      32.388      11.077 
                     47              36      31.112      18.531      12.581 
                     48              32      19.922       5.025      14.897 
                     49               2      31.641      16.667      14.974 
                     50              45      38.313      15.287      23.026 
SPEARMAN CORR Procedure % White 
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N=50 
Tonne with Holly 
The CORR Procedure 
 
                                  1 With Variables:    plqpwh06 
                                  1      Variables:    plqpwh049 
                                       Simple Statistics 
 
  Variable            N          Mean       Std Dev        Median       
Minimum       Maximum 
  plqpwh06           50      36.03688      17.53580      33.46300       
4.68500      74.08900 
  plqpwh049          50      36.94592      15.91481      34.49650       
3.31100      76.22900 
 
 
                           Spearman Correlation Coefficients, N = 50 
                                   Prob > |r| under H0: Rho=0 
                                                  plqpwh049 
                                    plqpwh06        0.86218 
                                                     <.0001 
 
Spearman correlation between Tonee and Holly is 0.86 
p-value <0.0001  
Pearson correlation is: 0.89 
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Intraclass correlation between Tonee and Holly Percent White 
 
                      Variance Components Estimation Procedure 
 
                                    Class Level Information 
 
Class       Levels  Values 
 
id              50  1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 
23 24 25 26 27 28 
                    29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 
48 49 50 
 
tech             2  6 49 
 
 
                                 Number of observations    100 
 
 
                                 Dependent Variable:    PlqPWh 
 
 
                                  Type 1 Analysis of Variance 
 
                                Sum of 
 Source               DF       Squares   Mean Square  Expected Mean Square 
 
 tech                  1     20.658843     20.658843  Var(Error) + 50 
Var(tech) 
 id                   49         25933    529.238458  Var(Error) + 2 Var(id) 
 Error                49   1545.792072     31.546777  Var(Error) 
 Corrected Total      99         27499             .  . 
 
 
                                        Type 1 Estimates 
 
                               Variance Component        Estimate 
 
                               Var(tech)                 -0.21776 
                               Var(id)                  248.84584 
                               Var(Error)                31.54678 
 280.17486 
 
Intraclass correlation:  
89% of the variation is % white was due to differences between participants. 
 
ICC=var % White between participants / Total variability= 
248.84584/280.17486=0.89 
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Bland-Altman 
Tonee and Holly for Percent White Differences 
Normality for Percent White Diff between Tonee and Holly 
 
                                       The REG Procedure 
                                         Model: MODEL1 
                                 Dependent Variable: pwhdiffTH 
 
                                 Analysis of Variance 
                                        Sum of           Mean 
    Source            DF        Squares         Square    F Value    Pr > F 
 
    Model             1      136.10733      136.10733       2.21    0.1436 
    Error             48     2955.47682       61.57243 
    Corrected Total   49     3091.58414 
 
 
                      Root MSE              7.84681    R-Square     0.0440 
                      Dependent Mean        0.90904    Adj R-Sq     0.0241 
                      Coeff Var           863.19748 
Parameter Estimates 
 
                                                    Parameter      Standard 
Variable    Label      DF      Estimate         Error   t Value   Pr > |t| 
 
Intercept   Intercep   1      4.64776       2.74861      1.69     0.0973 
meanpwhth the mean of 1      -0.10245       0.06891     -1.49     0.1436 
the percent white of tonee  
and Holly for Bland-Altman 
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KAPPA Statistic 
Tonee and Holly 
Automated Classification Variable 
 
 
 
KAPPA 
Tonee and Holly 
Automated CLASS Variable 
 
                                       The FREQ Procedure 
 
                                 Table of auto_c049 by auto_c06 
 
 
                                    Simple Kappa Coefficient 
                                Kappa                     0.6067 
                                ASE                       0.1329 
                                95% Lower Conf Limit      0.3463 
                                95% Upper Conf Limit      0.8672 
 
                                        Sample Size = 50 
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Appendix A.1 
Distributions of the Difference variables for GSM and Percent White 
 
                                    The UNIVARIATE Procedure 
                                      Variable:  gsmdiffTD 
 
           N                          50    Sum Weights                 50 
           Mean                     3.46    Sum Observations           173 
           Std Deviation      8.59570372    Variance            73.8861224 
           Skewness           0.07758774    Kurtosis            -0.3403995 
           Uncorrected SS           4219    Corrected SS           3620.42 
           Coeff Variation    248.430743    Std Error Mean      1.21561608 
 
                                   Basic Statistical Measures 
 
                         Location                    Variability 
 
                     Mean      3.46000     Std Deviation            8.59570 
                     Median    4.00000     Variance                73.88612 
                     Mode     -1.00000     Range                   38.00000 
                                           Interquartile Range     14.00000 
 
             NOTE: The mode displayed is the smallest of 2 modes with a count 
of 4. 
 
                                   Tests for Location: Mu0=0 
 
                        Test           -Statistic-    -----p Value------ 
 
                        Student's t    t  2.846293    Pr > |t|    0.0064 
                        Sign           M       5.5    Pr >= |M|   0.1524 
                        Signed Rank    S     259.5    Pr >= |S|   0.0084 
 
 
                                      Tests for Normality 
 
                   Test                  --Statistic---    -----p Value------ 
 
                   Shapiro-Wilk          W     0.987359    Pr < W      0.8663 
                   Kolmogorov-Smirnov    D     0.078072    Pr > D     >0.1500 
                   Cramer-von Mises      W-Sq  0.034034    Pr > W-Sq  >0.2500 
                   Anderson-Darling      A-Sq  0.220882    Pr > A-Sq  >0.2500 
 
 
                                    Quantiles (Definition 5) 
 
                                     Quantile      Estimate 
 
                                     100% Max          24.0 
                                     99%               24.0 
                                     95%               16.0 
                                     90%               13.5 
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                                    The UNIVARIATE Procedure 
                                      Variable:  gsmdiffTD 
 
                                    Quantiles (Definition 5) 
 
                                     Quantile      Estimate 
 
                                     75% Q3            11.0 
                                     50% Median         4.0 
                                     25% Q1            -3.0 
                                     10%               -6.5 
                                     5%               -12.0 
                                     1%               -14.0 
                                     0% Min           -14.0 
 
 
                                      Extreme Observations 
 
                              ----Lowest----        ----Highest--- 
 
                              Value      Obs        Value      Obs 
 
                                -14        1           14       42 
                                -13        6           15       46 
                                -12        4           16       44 
                                 -9       15           21       39 
                                 -7       14           24       32 
 
 
 
 
 
 
 
 
 
 
 
Univariate 
GSM 
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                                    The UNIVARIATE Procedure 
                                      Variable:  gsmdiffTD 
 
                        Stem Leaf                     #             Boxplot 
                          24 0                        1                | 
                          22                                           | 
                          20 0                        1                | 
                          18                                           | 
                          16 0                        1                | 
                          14 00                       2                | 
                          12 00000                    5                | 
                          10 0000                     4             +-----+ 
                           8 0                        1             |     | 
                           6 000000                   6             |     | 
                           4 00000                    5             *-----* 
                           2 000                      3             |  +  | 
                           0 00                       2             |     | 
                          -0 0000                     4             |     | 
                          -2 000                      3             +-----+ 
                          -4 00000                    5                | 
                          -6 000                      3                | 
                          -8 0                        1                | 
                         -10                                           | 
                         -12 00                       2                | 
                         -14 0                        1                | 
                             ----+----+----+----+ 
 
 
                                         Normal Probability Plot 
                        25+                                               * 
++ 
                          |                                               ++ 
                        21+                                           * ++ 
                          |                                          +++ 
                        17+                                        +* 
                          |                                      *+* 
                        13+                                  ***+ 
                          |                               **++ 
                         9+                               *+ 
                          |                           ***+ 
                         5+                         **+ 
                          |                       **+ 
                         1+                     +** 
                          |                   *** 
                        -3+                 ** 
                          |             **** 
                        -7+            *+ 
                          |          *+ 
                       -11+        +* 
                          |   * ++* 
                       -15+   ++ 
                           +----+----+----+----+----+----+----+----+----+----
+ 
                               -2        -1         0        +1        +2 
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                                    The UNIVARIATE Procedure 
                                      Variable:  pwhdiffTD 
 
           N                          50    Sum Weights                 50 
           Mean                  3.03652    Sum Observations       151.826 
           Std Deviation      7.78658291    Variance            60.6308735 
           Skewness           0.08029345    Kurtosis            -0.6967464 
           Uncorrected SS     3431.93549    Corrected SS         2970.9128 
           Coeff Variation    256.431142    Std Error Mean      1.10118912 
 
                                   Basic Statistical Measures 
 
                         Location                    Variability 
 
                     Mean     3.036520     Std Deviation            7.78658 
                     Median   1.831500     Variance                60.63087 
                     Mode      .           Range                   30.15400 
                                           Interquartile Range     11.86100 
 
 
                                   Tests for Location: Mu0=0 
 
                        Test           -Statistic-    -----p Value------ 
 
                        Student's t    t  2.757492    Pr > |t|    0.0082 
                        Sign           M         8    Pr >= |M|   0.0328 
                        Signed Rank    S     243.5    Pr >= |S|   0.0172 
 
                                      Tests for Normality 
 
                   Test                  --Statistic---    -----p Value------ 
 
                   Shapiro-Wilk          W     0.973236    Pr < W      0.3118 
                   Kolmogorov-Smirnov    D      0.08086    Pr > D     >0.1500 
                   Cramer-von Mises      W-Sq  0.061436    Pr > W-Sq  >0.2500 
                   Anderson-Darling      A-Sq  0.386716    Pr > A-Sq  >0.2500 
 
 
                                    Quantiles (Definition 5) 
                                     Quantile      Estimate 
 
                                     100% Max       17.5410 
                                     99%            17.5410 
                                     95%            15.9250 
                                     90%            15.1385 
                                     75% Q3          9.3150 
                                     50% Median      1.8315 
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                                    The UNIVARIATE Procedure 
                                      Variable:  pwhdiffTD 
 
                                    Quantiles (Definition 5) 
 
                                     Quantile      Estimate 
 
                                     25% Q1         -2.5460 
                                     10%            -6.3235 
                                     5%            -11.0750 
                                     1%            -12.6130 
                                     0% Min        -12.6130 
 
 
                                      Extreme Observations 
 
                            -----Lowest-----        -----Highest---- 
 
                              Value      Obs          Value      Obs 
 
                            -12.613        1         15.425       46 
                            -11.245        2         15.913       47 
                            -11.075        3         15.925       48 
                             -8.056        4         16.266       49 
                             -7.040        5         17.541       50 
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Normality for GSMDIFF between Tonee and Holly 
 
                                    The UNIVARIATE Procedure 
                                      Variable:  gsmdiffTH 
 
           N                          50    Sum Weights                 50 
           Mean                    -2.06    Sum Observations          -103 
           Std Deviation      10.9085437    Variance            118.996327 
           Skewness           0.00485671    Kurtosis             -0.637477 
           Uncorrected SS           6043    Corrected SS           5830.82 
           Coeff Variation    -529.54096    Std Error Mean      1.54270105 
 
                              Basic Statistical Measures 
 
                         Location                    Variability 
 
                     Mean     -2.06000     Std Deviation           10.90854 
                     Median   -2.50000     Variance               118.99633 
                     Mode     -3.00000     Range                   44.00000 
                                           Interquartile Range     15.00000 
 
 
                                   Tests for Location: Mu0=0 
 
                        Test           -Statistic-    -----p Value------ 
 
                        Student's t    t  -1.33532    Pr > |t|    0.1879 
                        Sign           M        -3    Pr >= |M|   0.4709 
                        Signed Rank    S      -123    Pr >= |S|   0.2101 
 
 
                                      Tests for Normality 
 
                   Test                  --Statistic---    -----p Value------ 
 
                   Shapiro-Wilk          W     0.985225    Pr < W      0.7812 
                   Kolmogorov-Smirnov    D     0.074674    Pr > D     >0.1500 
                   Cramer-von Mises      W-Sq  0.027694    Pr > W-Sq  >0.2500 
                   Anderson-Darling      A-Sq  0.177757    Pr > A-Sq  >0.2500 
 
 
                                    Quantiles (Definition 5) 
 
                                     Quantile      Estimate 
 
                                     100% Max          19.0 
                                     99%               19.0 
                                     95%               18.0 
                                     90%               12.5 
                                     75% Q3             5.0 
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Normality for GSMDIFFbetween Tonee and Holly5 
 
                                    The UNIVARIATE Procedure 
                                      Variable:  gsmdiffTH 
 
                                    Quantiles (Definition 5) 
 
                                     Quantile      Estimate 
 
                                     50% Median        -2.5 
                                     25% Q1           -10.0 
                                     10%              -15.5 
                                     5%               -21.0 
                                     1%               -25.0 
                                     0% Min           -25.0 
                                      Extreme Observations 
 
                              ----Lowest----        ----Highest--- 
                              Value      Obs        Value      Obs 
 
                                -25        3           13       31 
                                -22        9           14       34 
                                -21        7           18       45 
                                -18        8           18       47 
                                -16       24           19        2 
 
Normality for Percent White Diff between Tonee and Holly 
                                    The UNIVARIATE Procedure 
                                      Variable:  gsmdiffTH 
 
                        Stem Leaf                     #             Boxplot 
                          18 000                      3                | 
                          16                                           | 
                          14 0                        1                | 
                          12 000                      3                | 
                          10                                           | 
                           8 000                      3                | 
                           6 00                       2                | 
                           4 0000                     4             +-----+ 
                           2 0000                     4             |     | 
                           0 000                      3             |     | 
                          -0 0                        1             |     | 
                          -2 00000                    5             *--+--* 
                          -4 0                        1             |     | 
                          -6 000                      3             |     | 
                          -8 000                      3             |     | 
                         -10 000                      3             +-----+ 
                         -12 000                      3                | 
                         -14 000                      3                | 
                         -16 0                        1                | 
                         -18 0                        1                | 
                         -20 0                        1                | 
                         -22 0                        1                | 
                         -24 0                        1                | 
 
                   Normality for Percent White Diff between Tonee and Holly         
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                                    The UNIVARIATE Procedure 
                                      Variable:  gsmdiffTH 
 
                                         Normal Probability Plot 
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Normality for Percent White Diff between Tonee and Holly 
 
                                    The UNIVARIATE Procedure 
                                      Variable:  pwhdiffTH 
 
                                            Moments 
 
             N                          50    Sum Weights                 50 
             Mean                  0.90904    Sum Observations        45.452 
             Std Deviation      7.94314509    Variance             63.093554 
             Skewness           0.22638338    Kurtosis             0.4592752 
             Uncorrected SS     3132.90183    Corrected SS        3091.58414 
             Coeff Variation    873.794893    Std Error Mean      1.12333035 
 
 
                                   Basic Statistical Measures 
 
                         Location                    Variability 
 
                     Mean     0.909040     Std Deviation            7.94315 
                     Median   0.335500     Variance                63.09355 
                     Mode      .           Range                   42.02200 
                                           Interquartile Range     10.30200 
 
 
                                   Tests for Location: Mu0=0 
 
                        Test           -Statistic-    -----p Value------ 
 
                        Student's t    t  0.809237    Pr > |t|    0.4223 
                        Sign           M         3    Pr >= |M|   0.4799 
                        Signed Rank    S      70.5    Pr >= |S|   0.5017 
 
 
                                      Tests for Normality 
 
                   Test                  --Statistic---    -----p Value------ 
 
                   Shapiro-Wilk          W     0.986818    Pr < W      0.8461 
                   Kolmogorov-Smirnov    D     0.079041    Pr > D     >0.1500 
                   Cramer-von Mises      W-Sq  0.050191    Pr > W-Sq  >0.2500 
                   Anderson-Darling      A-Sq  0.287525    Pr > A-Sq  >0.2500 
 
 
                                    Quantiles (Definition 5) 
 
                                     Quantile      Estimate 
 
                                     100% Max       23.0260 
                                     99%            23.0260 
                                     95%            14.8970 
                                     90%            10.9930 
                                     75% Q3          6.0630 
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                   Normality for Percent White Diff between Tonee and Holly 
 
                                    The UNIVARIATE Procedure 
                                      Variable:  pwhdiffTH 
 
                                    Quantiles (Definition 5) 
 
                                     Quantile      Estimate 
 
                                     50% Median      0.3355 
                                     25% Q1         -4.2390 
                                     10%            -8.6620 
                                     5%            -10.1270 
                                     1%            -18.9960 
                                     0% Min        -18.9960 
 
                                      Extreme Observations 
                            -----Lowest-----        -----Highest---- 
                              Value      Obs          Value      Obs 
 
                            -18.996        7         11.077       39 
                            -11.553       41         12.581       36 
                            -10.127        4         14.897       32 
                             -9.719       38         14.974        2 
                             -9.156        8         23.026       45 
                   Normality for Percent White Diff between Tonee and Holly  
 
                                    The UNIVARIATE Procedure 
                                      Variable:  pwhdiffTH 
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                                    The UNIVARIATE Procedure 
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APPENDIX E: FINAL PROTOCOL FOR NEXT GRANT SUBMISSION 
E.1 SUBCLINICAL CARDIOVASCULAR DISEASE IN LUPUS 
Very few investigators have examined the prevalence of carotid plaque and IMT in lupus using 
B-mode ultrasound.(1) (2) (3;4)  We previously reported the presence of focal carotid plaque in a 
sample of CVD-free lupus women as 32% and the mean IMT as 0.71mm.  In 175 unselected 
women with lupus, focal carotid plaque prevalence was 40%.(1)  The inclusion of women with 
previous cardiovascular events in the second study may explain the higher   prevalence.  In a 
recent study by Roman et al.(4), 197 patients with lupus and 197 matched controls were 
evaluated with carotid ultrasonography and assessed for risk factors for cardiovascular disease.  
 The traditional risk factors for cardiovascular disease were similar among patients and 
controls.  Carotid plaque was more prevalent among patients than the controls (37.1 percent vs. 
15.2 percent, P<0.001). In multivariate analysis, older age, the presence of lupus (odds ratio, 4.8; 
95 percent confidence interval, 2.6 to 8.7), and a higher serum cholesterol level were 
independently related to the presence of plaque. As compared with lupus patients without plaque, 
patients with plaque were older, had a longer duration of lupus and more disease-related damage, 
and were less likely to have been treated with prednisone, cyclophosphamide, or 
hydroxychloroquine. In multivariate analyses including patients with lupus, independent 
predictors of plaque were a longer duration of disease, a higher damage-index score, a lower 
incidence of the use of cyclophosphamide, and the absence of anti-Smith antibodies.  These data 
support our finding that variables related to lupus disease activity are important predictors of 
cardiovascular disease, and that immunosuppressive therapy is associated with less progression 
of carotid IMT.  
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E.2 LUPUS FACTORS THAT MAY PROMOTE CARDIOVASCULAR DISEASE 
PROGRESSION  
We believe that the pathogenesis of cardiovascular disease in lupus is multifactorial, due to an 
interaction between traditional cardiovascular risk factors and inflammation-induced and 
antiphospholipid antibody-mediated vascular injury/thrombosis from the underlying disease.  
Renal disease with resulting hypertension may accelerate the atherosclerotic process in lupus. 
While we know that atherosclerotic plaques are the root cause of stroke and myocardial 
infarction, we still know little about why one arterial plaque causes an event and another does 
not.  In the past, the degree to which a plaque narrows a given vessel and reduces blood flow was 
thought to be the primary determinant of its danger.  However, in recent years, it has become 
clear that plaque rupture is the key determinant of a vascular event (5-9). Plaque rupture can 
occur in both large and medium plaques and thus the determinant appears to be plaque 
composition as opposed to solely plaque size.(6;10-12) 
Women with lupus are known to be at high risk for cardiovascular disease.(11;13;14)  
Our own work and that of others has suggested that risk factors specific to the lupus disease 
process may have a particularly strong effect on plaque development.  From a biological 
perspective, this makes sense because lupus brings with it abnormalities in platelet function, and 
thrombotic and inflammatory processes, all of which are related to plaque development and 
progression. 
This raises the question of whether the high prevalence of CVD among women with 
lupus is related to a propensity to develop unstable plaques.  Since the realization that plaque 
composition is likely the major driver of risk, researchers have been searching for a way to 
identify vulnerable or unstable plaques in vivo.  Standard ways of evaluating plaques using 
ultrasound have been developed and automated software methods that are on the horizon are 
showing even more promise.(15-17)  In general, individuals with echolucent or heterogeneous 
lesions have been shown to be at high risk for events relative to individuals with other plaque 
types.(10;18-21)  
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E.3 EVALUATION OF PLAQUE AND PLAQUE COMPOSITION: 
During scanning, the sonographer will digitize images of all plaques.  As part of our 
standard plaque evaluation, the number and size of plaques in each segment will be recorded.  
Plaque will be assessed in 4 areas: proximal common, distal common, carotid bulb and internal 
carotid.  Plaques typically occur in the carotid bulb and proximal ICA where flow disturbances 
occur due to the carotid bifurcation.  We expect plaques in the CCA to be rare. 
We will use three separate methodologies to evaluate plaque in this study: The plaque 
index, a subjective measure of the degree of plaque, the Gray-Weale scale, a subjective scale of 
plaque quality, and finally an objective measure of plaque density using a computerized scoring 
system.  
Plaque Index:  The plaque index is reproducible(22) and has been used as a measure of 
focal plaque in numerous population.(23-26) In each carotid segment, the number of distinct 
plaques will be recorded.  In addition, each segment will be given a grade, which corresponds to 
both the number and size of plaques.  These grades will be defined as follows: Grade 0 = no 
observable plaque; grade 1 = one small plaque (less than 30% of the vessel diameter); grade 2 = 
one medium plaque (between 30% and 50% of the vessel diameter) OR multiple small plaques; 
grade 3 = one large plaque (greater than 50% of the vessel diameter) or multiple plaques with at 
least one medium plaque.  The grades will then be summed to create the plaque index, a measure 
of extent of eccentric plaque. 
Gray-Weale Scale:  Studies using subjective scales from ultrasound have been useful in 
learning about lesion description and vulnerability. A subjective categorization was reported by 
Gray-Weale(27) and similar scales by other investigators.(11;28;29)  The Gray-Weale scoring is 
as follows: type 1, dominantly echolucent; (similar to blood) type 2, dominantly echolucent with 
small areas of echogenicity; type 3, substantially echogenic with few echolucent spots; type 4, 
uniformly echogenic; type 5 unclassified due to dense calcification and shadowing.   
Computerized Scoring of Plaque Density : This will be accomplished using the AMS 
(Automated Measuring System) software developed by Dr. Thomas Gustavsson at the Chalmers 
University of Technology in Götenberg, Sweden.  This software is similar to others that have 
been developed and used successfully.(19;30-32)  Over the past year we have been working to 
evaluate the software and learn how to use it.  Thus far we have scored 100 scans.  Because this 
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will be the first formal study we have done with this software, we have begin with a 
reproducibility study to ensure that our readers are properly trained and are yielding reproducible 
results.  
Plaque Scoring Protocol:  If more than one plaque is present in a given segment, the 
largest plaque will be chosen.  Images will be displayed on a monitor and calibrated. This will be 
accomplished by selecting an area on the image that is black (hypoechoic), such as the lumen 
and another area that is white (hyperechoic), such as tissue or plaque. The software will place 
these two extreme measures at opposite ends of a scale used to evaluate each pixel within the 
plaque. The reader then will outline the plaques with the cursor along the lumen-intima interface 
and along the media-adventitia interface. The system is prompted to electronically connect the 
dots to fully encompass the lesion.  Each pixel within the plaque is identified on the initial scale 
and several measurements are obtained by applying various complex algorithms.  
The gray-scale median (GSM) will be used to quantify overall plaque echogenicity. 
Lower GSM values have been shown to be associated with cerebral ischemia and symptoms 
.(20) (33;34)  To date, no one has tested the association between carotid echogenicity and 
cardiovascular symptoms. It is possible that like IMT, vulnerable carotid plaques may be a 
predictor of coronary disease.  
 Authors use a variety of descriptors for plaque that are not yet standardized. For 
our purposes, we begin with the density of blood as seen on ultrasound. Blood appears black on 
an ultrasound image, when gains are set properly, and this is used as our baseline. Our key 
descriptors will be as follows: 
 
Echolucent = less echogenic = hypoechoic = darker = appearing black like blood 
Echogenic = more echogenic = hyperechoic = brighter =appearing whiter than blood 
Heterogeneous = mixed echogenicity = both black and white echos 
Homogeneous = mostly uniform echogenicity = dominantly black, white or gray 
 
Most ultrasound studies report that plaques that resemble blood are most vulnerable and 
may contain thrombus compared to those on the other end of the scale (white).(15;27;35) 
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